Videos
Browse videos by topic
All Videos
Showing 1-24 of 1012 videos
Employer Best Practices for Working with Health Insurance Brokers
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Dec 7, 2025
This video provides an in-depth exploration of the "nested principal-agent problem" inherent in employer-sponsored health insurance plans, focusing on the misaligned incentives and informational asymmetry that drive up costs for organizations. Dr. Eric Bricker begins by analyzing the financial relationship between employers and health insurance brokers/benefit consultants. Using a specific example of an employer with 9,000 employees, he contrasts the direct fee paid by the employer ($175,000 annually) with the estimated commissions the broker receives from carriers, PBMs, and other vendors (approximated at $15 per employee per month, totaling $1.62 million annually). This stark 10x disparity immediately establishes the core conflict: the broker's primary loyalty lies with the carriers who provide the vast majority of their income, not the employer who hired them. The analysis then frames this conflict using the Principal-Agent Problem, where the Agent (e.g., HR, Broker, Carrier) acts on behalf of the Principal (e.g., CEO, HR, Broker), but fails to do so due to misaligned incentives and informational asymmetry. The video details a four-tiered "nested" structure: the Organization (Principal) to HR (Agent/Principal), to the Broker/Consultant (Agent/Principal), to the Insurance Carrier (Agent). Bricker explains that the organization cares most about cost control, while HR prioritizes ease of administration due to understaffing. Brokers seek to maximize revenue while minimizing client time, and carriers maximize revenue, often heavily reliant on pharmaceutical rebates/commissions paid to PBMs. Furthermore, informational asymmetry decreases dramatically down the chain, with CEOs knowing "nothing" about healthcare, HR having little experience, and brokers often misunderstanding basic carrier contracting details (like variations in in-network allowed amounts), while carriers possess nearly all the expertise. To combat these systemic issues, the video proposes real-world solutions categorized into incentive alignment and information enhancement. For incentive alignment, best practices include tying a significant portion (up to 20%) of HR’s bonus to the total health plan budget (fixed and variable costs). To manage brokers and carriers, the solution is mandatory competition: putting broker contracts and carrier contracts out to bid (RFP) every three years. This forces performance, as the broker is essentially bidding for the opportunity to earn the large commission stream. For informational solutions, organizations are advised to form benefits committees involving finance, HR, and employee leadership to mutually educate themselves on complex topics like PBM transparency and high-cost claimants. HR professionals must become "expert purchasers," learning contractual details and best practices from internal purchasing departments or specialized conferences. Finally, brokers are encouraged to gain expertise in provider payment mechanisms by engaging with organizations like the Hospital Financial Management Association (HFMA), ensuring they hear both the carrier and provider sides of the story to challenge carrier claims effectively. Key Takeaways: • **Broker Compensation Misalignment:** Health insurance brokers often earn nearly 10 times more in commissions from carriers and PBMs than they receive in direct fees from the employer, creating a fundamental conflict of interest where their loyalty is financially tied to the carrier. • **Nested Principal-Agent Problem:** The employer health plan structure involves four nested principal-agent relationships (Organization -> HR -> Broker -> Carrier), each layer suffering from misaligned incentives and decreasing levels of healthcare expertise moving away from the carrier. • **HR Incentive Alignment Best Practice:** High-performing organizations align HR incentives by basing up to 20% of HR compensation on the total health plan budget performance, covering both fixed costs (premiums, consulting fees) and variable claims costs. • **Mandatory Competition for Agents:** To hold brokers and carriers accountable, employers must commit to putting both broker contracts and carrier contracts out to bid (RFP) every three years; this competition is essential to prevent exploitation and secure better terms. • **Carrier Revenue Drivers:** Insurance carriers often derive substantial revenue not solely from premiums, but significantly from RX payments, specifically rebates or commissions paid by pharmaceutical companies to the PBMs they own or manage. • **Addressing Informational Asymmetry:** CEOs and HR departments typically lack deep healthcare finance expertise; solutions include forming a Benefits Committee (involving finance, HR, and employee leadership) to collectively and continuously educate stakeholders on plan details, PBMs, and high-cost claims. • **HR as Expert Purchasers:** HR professionals should adopt best practices from corporate purchasing departments, focusing on contractual details and attending purchasing conferences to improve their ability to negotiate and manage vendor relationships effectively. • **Broker Expertise in Provider Payment:** Brokers must gain deep knowledge of how carriers pay providers (e.g., understanding price transparency and allowed amounts) by engaging with provider-side financial organizations like the Hospital Financial Management Association (HFMA) to counter carrier narratives. • **Leveling Up Expertise:** To achieve top-tier performance, organizations should strive to develop expertise one level beyond their agent (e.g., the Organization becoming expert in purchasing, HR becoming expert in provider payment, and the Broker becoming expert in care provision). Tools/Resources Mentioned: * **HFMA (Hospital Financial Management Association):** A professional organization for CFOs and financial leaders of hospitals and physician practices, recommended for brokers seeking to understand provider payment mechanisms. * **Google/AI:** Suggested for finding public contracts between employers and benefit consultants to analyze fee structures. * **Purchaser Conferences:** Recommended for HR professionals to learn best practices in contractual negotiation and vendor management. Key Concepts: * **Principal-Agent Problem:** A conflict of interest arising when one party (the Agent) is expected to act in the best interest of another (the Principal), but has misaligned incentives and superior information, leading them to act in their own self-interest. * **Nested Principal-Agent Problem:** A chain of principal-agent relationships where the agent of one relationship becomes the principal of the next (e.g., Organization -> HR -> Broker -> Carrier). * **Informational Asymmetry:** A situation where one party in a transaction or relationship has more or better information than the other, which can be exploited (e.g., carriers knowing far more about healthcare finance than employers or brokers). * **"Whose bread I eat, his song I sing":** An ancient expression emphasizing that loyalty follows the source of income, explaining why brokers prioritize carriers over employers.
Why Did They Dismiss The J&J Lawsuit? | with Chris Hamilton
Self-Funded
@SelfFunded
Dec 5, 2025
The video provides an in-depth discussion of critical, current events shaping the pharmaceutical and healthcare insurance landscape, focusing heavily on drug cost transparency, fiduciary responsibility, and the accelerating role of technology, particularly AI. The conversation begins with an analysis of the dismissal of a major lawsuit against Johnson & Johnson regarding the mismanagement of employee prescription drug benefits. The speakers dissect the legal rationale—that plaintiffs failed to demonstrate "concrete harm"—and argue that systemic inefficiencies in PBM contracts, leading to higher premiums and out-of-pocket costs, constitute a breach of fiduciary duty. This segment highlights the profound conflict of interest inherent in traditional PBM models, where a $10,000 monthly medication cost through insurance could be purchased for $48 cash via alternative programs, illustrating the massive financial delta that employers and employees are forced to absorb. A key theme explored is the strategic interplay between pharmaceutical manufacturers and Pharmacy Benefit Managers (PBMs). This is exemplified by Eli Lilly's decision to switch its 23,000 employees from a "Big Three" PBM (CVS Caremark) to a transparent rival (Rightway). The move is strongly implied to be a response to the PBM's formulary decision to favor a rival GLP-1 drug (Novo Nordisk’s Wegovy) over Lilly’s Zepbound, underscoring how PBM relationships are intertwined with commercial access and market leverage for drug makers. Following this, the discussion shifts to regulatory changes, specifically the FDA’s move to speed up biosimilar approvals by relying more on analytical assessments rather than costly human efficacy studies. This regulatory shift is expected to significantly increase competition and drive substantial cost savings (often 10x to 12x) for high-cost specialty drugs like Humira and Stelara, offering employers new strategies for plan design, such as mandating biosimilar use or incentivizing adoption through zero-cost sharing for employees. Crucially, the speakers dedicate a significant portion of the analysis to the rapid adoption of Artificial Intelligence in healthcare, noting that the industry's deployment rate (22% in 2025) is seven times higher than the broader US economy. This surge is attributed to the industry's complexity and the massive opportunity to automate redundant administrative tasks, such as claims processing and dispute resolution (especially related to the No Surprises Act). While Big Pharma shows some hesitation, preferring to fine-tune proprietary AI models, the most impactful use cases discussed revolve around leveraging LLMs for data extraction and analysis. This includes ingesting complex contracts (MSAs, BAAs, PBM agreements) to rapidly identify fiduciary exposure, gag clauses, and conflicts of interest—a task that traditionally takes legal counsel weeks and tens of thousands of dollars. Furthermore, the speakers identify AI's potential to scrub hospital machine-readable files, marrying this pricing data with specific plan setups to create true shoppability for medical services, driving transparency and efficiency in healthcare consumerism. The conversation concludes by linking these cost drivers—PBM inefficiencies, rising hospital reimbursements, and catastrophic claims—to the current trend of extreme fully insured premium increases (up to 48% or more), reinforcing the need for employers to adopt innovative, data-driven strategies like self-funding and AI-powered contract scrutiny. Key Takeaways: • **PBM Fiduciary Risk and Contract Scrutiny:** The J&J lawsuit dismissal, despite the outcome, highlights the critical fiduciary liability employers face regarding PBM contract inefficiencies. AI/LLM solutions are essential for rapid, objective review of PBM contracts, MSAs, and BAAs to uncover hidden costs, gag clauses, and conflicts of interest that breach fiduciary responsibility. • **Pharma Commercial Strategy and PBM Conflict:** Eli Lilly's PBM switch illustrates the direct link between formulary decisions and commercial relationships. Pharma companies must strategically manage their employee benefit plans to align with their commercial interests and ensure favorable access for their own products, a decision that requires deep industry and PBM knowledge. • **Regulatory Impact on Biosimilar Market:** The FDA's push to accelerate biosimilar approval by focusing on analytical assessments over human efficacy studies will flood the market with lower-cost alternatives. Life sciences companies must anticipate this increased competition and adjust their market access and pricing strategies for biologics. • **AI Outpacing Economic Adoption:** Healthcare's high AI adoption rate (22% deployment) signals a massive opportunity for technology firms like IntuitionLabs.ai to address systemic inefficiencies, particularly in administrative burden reduction, claims processing, and dispute resolution (e.g., No Surprises Act claims). • **LLMs for Contract Intelligence:** Generative AI is highly effective for ingesting and analyzing complex legal and financial documents (e.g., stop-loss, pharmacy, and PBM contracts). This capability drastically reduces the time and cost associated with identifying financial exposure and non-compliant clauses compared to traditional legal review. • **Data-Driven Price Transparency:** A major positive use case for AI is scrubbing hospital machine-readable files and integrating this data with specific insurance plan designs. This enables true "shoppability" for medical services, allowing employers to direct members to high-quality, low-cost providers, potentially creating tier-one direct contract networks. • **Leveraging Real-Time Monitoring Data:** The rise of at-home monitoring devices (like CGMs) provides continuous, high-fidelity data that moves physician assessments beyond single point-in-time blood draws. Data engineering services are needed to integrate this real-time data into clinical workflows for better chronic disease management (e.g., diabetes). • **Addressing Fully Insured Premium Hikes:** Extreme premium increases (38% to 48%+) are driven by escalating hospital reimbursement rates and catastrophic claims. Employers are increasingly forced to consider self-funded models to gain visibility and control over claims data, allowing them to implement cost management strategies that are unavailable in fully insured arrangements. • **The Need for Informed Decision-Making:** Employers often lack the nuance to understand complex health insurance contracts. Consultants must guide employers to make "eyes wide open" business decisions, understanding the trade-offs of PBM partnerships and utilizing data to design plans that are financially efficient for the employer while simultaneously benefiting the employee (e.g., zero-cost biosimilars). Tools/Resources Mentioned: * **Veeva CRM:** (Implied context, as IntuitionLabs.ai specializes in Veeva consulting, though not explicitly mentioned in the transcript, the commercial operations focus is relevant.) * **Mark Cuban's Cost Plus Program:** Mentioned as a cash-pay alternative demonstrating massive drug cost savings. * **Express Scripts (Evernorth/Cigna):** Named as the PBM involved in the J&J lawsuit. * **CVS Caremark:** Implied as the "Big Three" PBM Eli Lilly switched from. * **Rightway:** Named as the transparent PBM rival Eli Lilly switched to. * **Smith Rx:** Mentioned as an example of a PBM that facilitates biosimilar switching. * **Home of Health:** A company mentioned that uses LLMs to ingest and analyze contracts for fiduciary exposure. Key Concepts: * **Fiduciary Liability (under ERISA):** The legal obligation of employers and named individuals running health plans to act solely in the interest of plan members, making the right decisions and evaluations to ensure efficient deployment of funds. * **Biosimilars:** Essentially generic alternatives to expensive specialty biologic drugs (e.g., Humira, Stelara), offering significant cost savings (often 90% or more) while maintaining comparable safety and efficacy. * **No Surprises Act (NSA):** Legislation intended to protect consumers from surprise out-of-network medical bills, which has led to a non-stop increase in disputes between carriers and providers, often requiring AI-driven solutions to manage the administrative load. * **Machine-Readable Files (MRFs):** Hospital-mandated files containing pricing data that, when scrubbed and analyzed by AI, can unlock true price transparency and shoppability for medical procedures. Examples/Case Studies: * **J&J Lawsuit:** A drug costing $10,000/month through the PBM could be purchased for $48 cash, illustrating the massive cost inefficiency and alleged fiduciary breach. * **Eli Lilly PBM Switch:** Lilly moved 23,000 employees from a major PBM after that PBM favored a rival drug (Novo Nordisk's GLP-1) on its formulary over Lilly's Zepbound. * **Biosimilar Cost Savings:** Humira biosimilars cost approximately $750-$850/month compared to $75,000-$85,000/year for the brand name, representing a 10x to 12x savings opportunity. * **Underwriting with AI:** An example was shared where initial AI outputs for underwriting were completely inaccurate, stressing the danger of relying on AI without a human expert (like an underwriter) who understands the financial context and can train the model effectively.
Interview With Andreas Gerloff, Daiichi Sankyo Europe - Veeva Commercial Summit
Moe Alsumidaie
/@Annexclinical
Dec 2, 2025
This video provides an in-depth exploration of the evolving strategic role of Medical Affairs (MA) within the pharmaceutical industry, featuring an interview with Andreas Gerloff, Director of Medical Excellence Operations at Daiichi Sankyo Europe, conducted at the Veeva Commercial Summit. The discussion centers on MA's shift from a support function to a strategic pillar alongside R&D and Commercial, the critical challenges in insight generation and impact measurement, and the disruptive potential of Artificial Intelligence (AI) and Generative AI (GenAI) in this domain. Gerloff emphasizes that while MA has achieved peer status in strategic planning across many organizations, a significant gap remains in aligning objectives and measuring success cross-functionally. The core challenge for MA is balancing the need for scientific depth with the pressure to deliver faster, actionable insights to R&D and Commercial teams. He notes that the MSL role has fundamentally changed from a data disseminator to a critical insight collector, focusing on understanding customer perception and alignment with company data. However, the industry struggles with a lack of robust processes and tools for internal processing, actioning insights, and effectively "closing the loop" back to the customer or strategy. This lack of agility makes it difficult to reshape strategy in real-time based on clinician feedback, particularly concerning evidence needs (80% of shared insights) and educational gaps (78% of shared insights). A major theme is the difficulty in measuring MA impact. Gerloff advocates for moving away from simple activity counting (e.g., number of ad boards or interactions) toward a comprehensive framework that tells a story. This framework should link objectives, activities, belief change, clinical behavior change, and ultimately, patient outcomes. The pressure to prove value and return on investment (ROI) for the significant investments made in MA over recent years necessitates this shift toward outcome-based metrics. Furthermore, the entire pharma operating model is being forced to reinvent itself due to more educated patients and changing HCP needs, particularly the preference for engaging with Medical Affairs over Commercial for scientific discussions, a trend accelerated by the COVID-19 pandemic. The interview concludes with a focused discussion on AI. Gerloff believes AI can impact nearly all process steps within MA, including insight collection, analysis, and personalization of communication. While pharma companies are currently in the early stages of internal experimentation and proof-of-concepts, a more profound concern is the external impact of GenAI on stakeholders. Citing an IQVIA report, he highlights that over 50% of HCPs (and 75% of those born after 1990) already use GenAI for scientific information and rank it closely in value to MSLs. This trend demands that pharma think critically about its role in medical education, ensuring accurate information is disseminated through these tools, especially since 14% of HCPs reportedly do not check GenAI sources before using the information for clinical decision-making. Gerloff suggests that the industry may need to overcome competitive barriers and collaborate to develop unified, authoritative GenAI solutions that serve as a single, trusted source of information for busy HCPs, preventing external sources from taking over the educational relationship. Key Takeaways: * **Strategic Alignment Gap:** While Medical Affairs (MA) has achieved strategic peer status with R&D and Commercial, a key challenge remains in achieving true alignment on shared objectives and developing unified metrics to measure joint success against overarching organizational goals. * **Insight Processing is the Bottleneck:** The primary struggle in leveraging insights (especially around evidence needs and educational gaps) is not collection, but the internal process—connecting data dots across channels (MSLs, advisory boards, medical info), translating data into action, and maintaining the agility to shape strategy in near real-time. * **Shift from Activity to Impact Measurement:** MA must transition from counting activities (e.g., number of interactions or ad boards) to using a range of metrics that demonstrate value along a chain of thought: objectives $\rightarrow$ activities $\rightarrow$ belief change $\rightarrow$ clinical behavior change $\rightarrow$ patient outcome. * **Proving ROI is Essential:** Significant recent investments in MA necessitate proving the return on investment (ROI) beyond simple sales numbers, requiring sophisticated measurement frameworks that capture the full scope of medical impact. * **Pharma Operating Model Reinvention:** The industry's operating model must reinvent itself due to evolving customer needs, including more educated patients and HCPs who increasingly prefer engaging with MA for scientific discussions, forcing MA to move beyond its traditional support role. * **AI's Internal and External Disruption:** AI is poised to impact all MA processes (KOL mapping, insight generation, personalization), but the greater concern is the external use of GenAI by HCPs (over 50% use it for scientific info), which threatens pharma's traditional role as the primary source of medical education. * **The Trust Deficit in GenAI:** A significant warning is that 14% of HCPs using GenAI for scientific information do not check the sources before using the information for clinical decision-making, highlighting a critical need for pharma to ensure the accuracy of information available via public tools. * **Need for Industry Collaboration on AI:** To maintain relevance and ensure accurate medical education, the industry should consider overcoming competitive barriers to collaborate on developing unified, authoritative GenAI solutions that serve as a single, trusted source for HCPs, rather than relying on individual company initiatives. * **MSL Role Transformation:** The MSL function has evolved from solely disseminating data to critically understanding customer perspectives and collecting high-value insights that inform cross-functional strategic planning. * **Cultural Shift for MA:** MA teams must continue to "step up," embrace difficult decision-making, and maintain a future-oriented perspective to ensure they remain strategic partners and do not miss mega-trends that could disrupt their relationship with customers. Tools/Resources Mentioned: * Veeva (Implied context of Veeva Commercial Summit and Veeva-developed frameworks/white papers) * IQVIA (Report cited regarding HCP use of GenAI) Key Concepts: * **Medical Excellence Operations:** The function responsible for optimizing the processes, tools, and strategic execution within a company’s Medical Affairs department. * **Insight Generation/Collection:** The process by which Medical Affairs gathers feedback from Key Opinion Leaders (KOLs) and clinicians regarding data gaps, evidence needs, and educational requirements related to a therapy or disease state. * **Medical Impact Measurement:** A framework designed to quantify the value and effectiveness of Medical Affairs activities, moving beyond simple metrics to show influence on clinical behavior and patient outcomes. * **GenAI in Medical Affairs:** The application of Generative AI and Large Language Models (LLMs) to automate tasks like KOL mapping, synthesize complex insights from disparate sources, and personalize scientific communication.
Office Politics in Health Insurance and Employee Healthcare... What CEOs Really Want.
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Nov 30, 2025
This video, presented by Dr. Eric Bricker, explores the underlying office politics and strategic priorities that drive CEO decision-making regarding employee health insurance and benefits. The central thesis is that CEOs do not primarily frame health plan decisions around the traditional "Triple Aim" of healthcare (cost, quality, access), but rather as a critical tool for managing organizational dynamics, maximizing retention, and successfully pushing the workforce, particularly the executive and middle management tiers, to work longer hours. The analysis begins by establishing the CEO's perspective: they are organizational leaders constantly "fighting fires" and view health insurance as a necessary cost (9% to 14% of total employee compensation) used solely to attract and retain talent. The speaker emphasizes that this decision-making occurs within the context of the organization's dominance hierarchy: the CEO, the Executive Leadership Team (ELT), Middle Management, and Frontline Workers. The CEO's primary challenge is a complex balancing act—pushing the organization to work more while minimizing turnover. This push for time is evidenced by the CEO's own high weekly hours (62.5 hours/week) and the general corporate desire for employees to return to the office (79% of CEOs want a full return, versus only 10% of remote-capable employees who agree). A critical insight derived from turnover statistics reveals the true focus of the CEO's loyalty. While overall annual turnover averages 18%, turnover for the ELT is only 5.2%, and for middle management, it is 6.3%. This disparity suggests a high degree of loyalty and retention among the upper tiers, which the CEO relies on heavily. Consequently, the CEO's health insurance strategy is implicitly designed to cater to and retain these most loyal and essential employees (ELT and middle management). The decision-making process is heavily influenced by the "web of loyalty" and internal drama surrounding money, power, and ego within the C-suite, often overshadowing concerns about improving healthcare quality or access for the broader workforce. The video concludes by reframing the role of HR, benefit consultants, and vendors. Success in this environment requires understanding and navigating this internal "bureaucracy" and web of loyalty, rather than simply presenting the best technical solutions (e.g., narrow networks, direct contracting). The CEO's ultimate strategy is cost-effectively pushing their most loyal employees to work harder while maximizing their retention, making the health plan a political instrument rather than a purely clinical or financial optimization tool. Key Takeaways: • **Health Insurance as a Political Tool:** CEOs view employee health plans primarily as an instrument for attracting and retaining key talent, not as a mechanism for achieving the healthcare industry's "Triple Aim" (cost, quality, access). • **Cost Context of Benefits:** Health and welfare benefits (medical, dental, vision, STD, LTD) constitute a significant line item, accounting for approximately 9% to 14% of total employee compensation, making cost management a constant priority for the CEO. • **Organizational Hierarchy Dictates Loyalty:** Corporate decision-making is heavily influenced by the organizational pyramid (CEO, ELT, Middle Management, Frontline Workers) and the complex relationships within the C-suite involving money, power, and ego. • **Retention Focus on Upper Tiers:** The CEO’s loyalty is concentrated on the Executive Leadership Team (ELT) and middle management, as evidenced by their significantly lower annual turnover rates (5.2% for ELT, 6.3% for middle management) compared to the overall average (18%). • **The Push for Productivity:** A core CEO objective is pushing the organization to work more; this is modeled by the CEO's own high work hours (62.5 hours/week) and the strong corporate desire for a return to the office (79% of CEOs support this). • **Strategic Framing for Vendors:** Consulting firms and vendors must frame their solutions (e.g., AI, CRM optimization) not just in terms of cost savings or technical excellence, but in how they support the CEO’s strategic goals of maximizing productivity and retention among the ELT and middle management. • **Navigating the Web of Loyalty:** Success for HR, benefit consultants, and technology vendors relies on understanding and navigating the internal office politics and the "web of loyalty" within the C-suite, often referred to as bureaucracy, as this dynamic drives decision-making more than technical merit. • **Misalignment on Work-Life Balance:** There is a significant disconnect between CEO expectations and employee desires regarding work time; nearly 80% of CEOs want a full return to the office, while only 10% of remote-capable employees agree, highlighting a constant internal battle for employee time. • **The CEO's Core Strategy:** The ultimate, unstated strategy of the CEO regarding the health plan is to cost-effectively push their most loyal employees (ELT and middle management) to work harder while simultaneously maximizing their retention. Key Concepts: * **ELT (Executive Leadership Team):** The group of direct reports to the CEO, characterized by high loyalty and low turnover, making them the primary focus of retention strategies. * **Web of Loyalty:** The complex network of relationships, power dynamics, and loyalty structures within the corporate hierarchy that dictates resource allocation and strategic decision-making, particularly concerning employee benefits. * **Total Employee Compensation:** The full cost of an employee, where health and welfare benefits typically account for 9% to 14% of the total, making it a major financial consideration for the CEO.
IBM, Veeva, V4C & Hitachi Hiring NOW | Freshers 2025 | Apply Links + How to Apply (PAN-India)
India’s Jobee – IT & MNC Job Updates
/@indiasjobee
Nov 29, 2025
This video serves as a comprehensive job alert, detailing current entry-level and fresher hiring opportunities across major multinational corporations (MNCs) in India, specifically focusing on roles available in 2025. The primary purpose is to provide candidates with direct application links, eligibility criteria, and a step-by-step guide on the application process for positions at IBM, Veeva, V4C, and Hitachi. The presentation is structured around quickly introducing each company and its specific open role, followed by practical advice on resume tailoring and interview preparation, aiming to maximize the success rate for applicants. The core of the video breaks down four distinct hiring drives. First, it highlights Hitachi’s internship program, noting a stipend of ₹21,000 and job locations in Hyderabad, Pune, and Bengaluru. Second, the focus shifts to IBM, which is actively recruiting for the Associate System Engineer role (Job ID: 66789) across various locations in India. Third, a specific data role is covered: the Associate Data Engineer position at V4C, located in Pune, Maharashtra. Crucially for the life sciences technology sector, the fourth major opening discussed is the Associate Software Engineer (Test Automation) role at **Veeva Systems**, a full-time position based in Hyderabad, India. The speaker emphasizes that all necessary application links and detailed eligibility checks are provided in the video description, streamlining the job search process for fresh graduates. Beyond simply listing openings, the video adopts a practical, candidate-focused approach. It offers actionable guidance, including how to tailor resumes specifically for data, software, and systems engineering roles, and provides example subject lines for applications. Furthermore, the video includes a quick walkthrough of the application process to avoid common mistakes and offers a high-impact, seven-day interview preparation plan. This structure ensures that the content delivers immediate value by connecting candidates to opportunities and equipping them with the necessary tools and strategies to succeed in the competitive entry-level tech hiring landscape across India. Key Takeaways: • **Veeva Systems is actively expanding its technical footprint in India:** The specific hiring for an Associate Software Engineer (Test Automation) in Hyderabad signals Veeva’s continued investment in its product development and quality assurance capabilities outside the US, which is crucial for the ecosystem of firms supporting Veeva CRM. • **Focus on Test Automation indicates platform maturity and regulatory requirements:** The specific requirement for a Test Automation role at Veeva suggests a strong emphasis on quality, reliability, and automated validation, which is paramount in regulated environments like pharmaceuticals where Veeva operates. • **Talent acquisition trends show demand for specialized entry-level roles:** The listed roles—Associate Data Engineer (V4C), Associate Software Engineer (Veeva), and Associate System Engineer (IBM)—highlight the broad demand for specific technical skills (data pipelines, automation, systems integration) among fresh graduates in the Indian market. • **Geographic distribution of tech roles is shifting:** The video points out specific job locations like Pune (V4C), Hyderabad (Veeva, Hitachi), and Bengaluru (Hitachi), confirming that major tech hiring is distributed across multiple Tier 1 and Tier 2 cities, not solely concentrated in Bengaluru. • **Application strategy must be role-specific:** The presenter stresses the importance of tailoring resumes for distinct roles (Data vs. Software vs. Systems), advising applicants to adjust their bullet points and subject lines to pass initial screening tests and automated resume filters. • **Direct application links are provided for efficiency:** The video’s core value proposition is the consolidation of direct application links for all four companies (Veeva via Lever, V4C via Workable, IBM via IBM Global, Hitachi via Naukri/Hitachi Careers), significantly reducing the search friction for candidates. • **IBM's mass hiring is identified by a specific Job ID:** The mention of IBM's Associate System Engineer role with Job ID 66789 provides a precise identifier for tracking this large-scale, PAN-India hiring drive, which is a key indicator of the general health of the IT sector. • **Internships remain a critical entry point:** Hitachi's focus on internships with a competitive stipend (₹21,000) underscores the importance of early career experience for securing full-time roles in major MNCs. • **Interview preparation should be high-impact and time-bound:** The video recommends a focused, seven-day preparation plan, suggesting that candidates prioritize high-impact study areas rather than broad, unfocused preparation for initial screening rounds. Tools/Resources Mentioned: * **Veeva Jobs Portal (Lever):** Used for the Associate Software Engineer application. * **V4C Jobs Portal (Workable):** Used for the Associate Data Engineer application. * **IBM Global Careers:** Used for the Associate System Engineer application. * **Hitachi Careers / Naukri:** Used for campus and off-campus opportunities. * **Resume Template:** A downloadable resource offered by the presenter to assist freshers. Key Concepts: * **Test Automation:** The practice of using software tools to control the execution of tests and the comparison of actual outcomes with predicted outcomes, essential for maintaining high quality and compliance in regulated software like Veeva. * **Associate System Engineer (ASE):** A common entry-level role at large IT services firms (like IBM) focusing on system maintenance, integration, and basic software development tasks. * **Off-Campus Drive:** Recruitment efforts conducted by companies targeting students who are not part of the official campus placement process, typically involving online assessments and interviews.
Veeva Commercial Summit 25: On quality data foundations and industry AI adoption with Karl Goossens
pharmaphorum media limited
/@Pharmaphorum
Nov 26, 2025
This video provides an in-depth exploration of the critical role of robust data foundations in enabling the successful adoption and scaling of Artificial Intelligence (AI) in commercial biopharma. Featuring Karl Goossens, General Manager of OpenData Europe at Veeva Systems, the discussion is set against the backdrop of the Veeva Commercial Summit 2025 in Madrid. Goossens shares key findings from Veeva's "The State of Data, Analytics, and and AI in Commercial Biopharma" report, which highlights a significant industry paradox: while AI adoption is accelerating, a staggering 89% of companies struggle to scale more than half their AI initiatives due to inadequate data foundations. The report, based on a survey of 116 senior life sciences leaders overseeing commercial analytics and AI, underscores the urgent need for business leaders to prioritize building strong data infrastructure to truly unlock AI's potential. The conversation delves into three core data issues identified by the report as hindering AI's impact: trust, speed, and consistency. Goossens explains that 73% of respondents reported insufficient data quality for AI applications, citing the need for highly accurate physician data (e.g., place of work) to generate meaningful insights. Speed is hampered by data fragmentation, with 63% of respondents noting that data scattered across disparate systems leads to lengthy "time to insight," often taking months to collect, map, and analyze data, rendering it too slow for timely decision-making. Consistency is another major challenge, as data about individuals often varies across different datasets, making global analytics and precise targeting (e.g., identifying doctors treating specific conditions) incredibly difficult, as illustrated by one customer having 30,000 different specialty values for physicians. To address these foundational challenges, Goossens introduces Veeva's latest innovations, particularly OpenData 2.0, designed to unify and standardize HCP (Healthcare Professional) and HCO (Healthcare Organization) data. A key innovation is "agentic data stewardship," which leverages AI to enhance data quality for the 26 million individuals in OpenData. This involves using AI to monitor public information in real-time, detecting changes like a physician's place of work, thereby providing account teams with up-to-date, accurate data for better AI recommendations. OpenData 2.0 also features a simpler, globalized data model that seamlessly integrates with Veeva software like Vault CRM, enabling consistent global analytics. Furthermore, it promotes data democratization through a web application that allows any customer employee to easily explore data, akin to LinkedIn, and offers a direct data API for rapid data transfer to AI models and analytics platforms, facilitating real-time insights. The discussion concludes with a forward-looking perspective, emphasizing AI's transformative potential for patients through faster R&D and personalized treatments, as well as its role in reducing healthcare costs by connecting fragmented data systems. Key Takeaways: * **Critical Data Foundation for AI Scaling:** Despite accelerating AI adoption in biopharma, 89% of companies fail to scale more than half their AI initiatives due to poor data foundations. Building a robust data foundation is paramount for unlocking AI's full value. * **Three Core Data Issues:** The report identifies Trust, Speed, and Consistency as the primary data challenges. Data quality is often insufficient (73% of respondents), data fragmentation hinders "time to insight" (63% experience delays of months), and inconsistent data across systems makes global analytics and precise targeting difficult. * **Importance of Unified HCP/HCO Data:** Unlocking the full potential of AI, especially generative AI, requires connecting and standardizing HCP and HCO data from various sources (research, patient types, work locations) to provide comprehensive information for AI models. * **Agentic Data Stewardship:** Veeva's innovation uses AI to proactively enhance data quality for millions of individuals in OpenData. This involves real-time monitoring of public information to detect changes (e.g., physician's workplace), ensuring data accuracy for better AI recommendations and tactical adjustments. * **OpenData 2.0 Innovations:** This evolution focuses on three elements: a new, simpler, globalized data model for consistent analytics and seamless integration with Veeva software (e.g., Vault CRM); data democratization via an intuitive web application for easy data exploration by any customer employee; and a direct data API for rapid data transfer to AI models and analytics platforms, enabling real-time insights. * **Understanding Agentic AI:** Agentic AI leverages Large Language Models (LLMs) to process both structured and unstructured data. It employs multiple specialized "agents" to perform distinct tasks, such as browsing the internet for information, answering questions (like chatbots), combining answers, and facilitating human quality checks, leading to more comprehensive and accurate data curation. * **Industry's AI Momentum:** The biopharma industry is actively moving beyond discussions to real-world deployment of AI initiatives, recognizing that correct data is a critical prerequisite for scaling these efforts. * **More Data, Better Quality, Global Curation:** The industry's current focus is on utilizing more data, ensuring higher data quality, and curating these datasets on a unified global data model to maximize AI's effectiveness. * **Patient-Centric AI Benefits:** AI promises significant benefits for patients, including faster R&D for new treatments, the ability to find the right treatment for the right patients, and empowering doctors with better diagnostic tools. * **Healthcare Cost Reduction:** Beyond patient care, AI has the potential to significantly reduce healthcare costs by connecting fragmented data systems, thereby minimizing duplicative procedures and improving overall system efficiency. Tools/Resources Mentioned: * Veeva Commercial Summit 2025 * Veeva's "The State of Data, Analytics, and AI in Commercial Biopharma" report * Veeva OpenData * Veeva OpenData 2.0 * Veeva Vault CRM * ChatGPT, Gemini (as examples of chatbots/LLMs) * LinkedIn (as an example of a web application for data exploration) Key Concepts: * **Agentic AI:** An advanced form of AI that utilizes multiple specialized "agents" (often powered by LLMs) to perform distinct tasks, process diverse data types (structured and unstructured), and collaborate to achieve complex goals, such as comprehensive data stewardship. * **Agentic Data Stewardship:** A specific application of agentic AI where AI agents continuously monitor, collect, process, and verify data (e.g., HCP information from public sources) in real-time to ensure high quality, accuracy, and consistency, often with a final human review. * **Data Fragmentation:** The issue of data being stored in multiple, disparate systems or silos within an organization, making it difficult to access, integrate, and analyze comprehensively. * **Time to Insight:** The duration it takes from data collection to generating actionable insights, often hindered by data fragmentation and poor data quality. * **Data Democratization:** Making data easily accessible and understandable to a wider range of users within an organization, empowering more employees to leverage data for decision-making without specialized technical skills. * **HCP (Healthcare Professional) and HCO (Healthcare Organization) Data:** Critical data pertaining to individual medical professionals and healthcare institutions, essential for commercial operations, medical affairs, and clinical research in the life sciences.
Veeva Commercial Summit 2025: On Data harmonisation with Alexander Ulrich
pharmaphorum media limited
/@Pharmaphorum
Nov 25, 2025
This video provides an in-depth analysis of Boehringer Ingelheim’s strategic initiative to standardize customer data globally, leveraging Veeva OpenData and Veeva Network, and the critical role this foundation plays in enabling advanced AI use cases and supporting their migration to Vault CRM. The discussion, featuring Alexander Ulrich, Global Head of System Integration & Data Ownership at Boehringer Ingelheim, emphasizes that data harmonization is not merely an operational task but a foundational necessity that underpins all subsequent commercial and medical affairs priorities. Boehringer Ingelheim, now the latest top 20 biopharma company to adopt this standardized approach across over 100 countries, views accurate and comprehensive customer reference data as essential for equipping teams with the insights needed to engage healthcare professionals (HCPs) effectively. Ulrich stresses that data quality and harmonization are the primary limiting factors for scaling AI technology within the pharmaceutical sector. While AI is rapidly evolving and offering new opportunities every few months, its success is entirely dependent on the quality and accessibility of the underlying data. A common pitfall noted is the belief that "AI will solve all my issues," which is often untrue if the foundational data ecosystem is not properly harmonized and available for the AI technology to leverage. This foundational work is crucial for supporting the company’s ongoing Vault CRM migration and ensuring the new system can deliver maximum value. A key objective of this data strategy is achieving a comprehensive 360-degree view of the HCP. The speaker explains that customer-facing functions often lack access to all relevant customer information, leading to suboptimal engagements. For instance, a representative might enter a conversation unaware that the HCP recently published research or spoke at a conference on a linked topic. The Customer 360 view, enabled by harmonized data, is necessary to provide these critical details at the representative's fingertips, leading to more relevant and impactful interactions with key opinion leaders (KOLs) and HCPs. Looking toward the future of engagement, the conversation highlights the disruptive potential of "agentic AI frameworks." Insights from the Commercial Summit suggest that the traditional model of engagement is changing rapidly. HCPs are increasingly relying on open evidence and accessing information through these AI frameworks, diminishing their reliance on Field Sales Liaisons (FSLs) or Medical Science Liaisons (MSLs) presenting clinical studies. The profound implication is that pharmaceutical companies may need to shift their engagement strategy from educating the final customer (the HCP) directly to educating the AI framework itself, allowing the framework to then disseminate information to the end-user. This suggests a future where certain customer-facing roles may be replaced or drastically redefined, much like the automation seen in other industries, requiring the industry to rapidly determine how to best work with this new technology for the benefit of customers and patients. Key Takeaways: • **Data Harmonization is Foundational for AI:** Standardizing customer data (using tools like Veeva OpenData and Veeva Network) is not a secondary task but a prerequisite for scaling AI use cases; poor data quality is the most significant limiting factor for successful AI implementation in pharma. • **Prerequisite for CRM Migration Success:** Harmonizing customer data is essential to support major platform shifts, such as migration to Veeva Vault CRM, ensuring that the new system is built upon a reliable, standardized data foundation from the outset. • **The AI-Data Quality Pitfall:** Companies must avoid the misconception that AI is a silver bullet; if the underlying data is not harmonized, accessible, and high-quality, AI solutions will fail to deliver expected results. • **Enabling Customer 360:** The goal of data harmonization is to provide a complete 360-degree view of the HCP, integrating information such as recent publications, conference appearances, and engagement history to facilitate more informed and valuable customer interactions. • **Shifting Engagement Models:** The industry is moving away from traditional reliance on FSLs/MSLs as the sole source of clinical information; HCPs are increasingly utilizing "open evidence" accessed via generative/agentic AI frameworks. • **The Need to Engage AI Frameworks:** Pharmaceutical companies must strategically pivot to educating the AI frameworks themselves, rather than solely focusing on direct engagement with the HCP, as these agents become the primary conduit for information delivery. • **Future Role Redefinition:** The rise of agentic AI solutions is expected to potentially replace or significantly change the job functions of various customer-facing roles within pharma, similar to historical automation shifts in other industries. • **Platform Education is Crucial:** Companies migrating to new platforms (like the new Veeva platform) must prioritize educating their internal teams on the full capabilities of the software to ensure maximum leverage and ROI. • **Leadership Alignment on Data Strategy:** Data harmonization requires buy-in and a common plan agreed upon by leadership and various functional groups, as it impacts all subsequent business priorities across the organization. • **Data as a Competitive Insight Tool:** Accurate customer reference data equips commercial teams with the necessary intelligence to tailor engagement and provide relevant information, moving beyond generic sales pitches. Tools/Resources Mentioned: * Veeva Commercial Summit 2025 * Veeva OpenData * Veeva Network * Veeva Vault CRM * Salesforce (mentioned as the platform Boehringer Ingelheim is moving away from) Key Concepts: * **Data Harmonization:** The process of standardizing and integrating customer reference data across multiple regions and systems (e.g., 100+ countries) to ensure consistency and quality. * **Agentic AI Frameworks:** Advanced Generative AI solutions capable of acting as autonomous agents, accessing and synthesizing open evidence and information, and potentially interacting directly with users (HCPs) in place of human representatives. * **Customer 360 View:** A comprehensive, unified perspective of a customer (HCP or KOL) that aggregates all relevant data points, including interactions, publications, and professional activities, to inform engagement strategy. * **Open Evidence:** Clinical or scientific data and research findings that are publicly accessible, often leveraged by AI frameworks to inform HCPs. Examples/Case Studies: * **Boehringer Ingelheim Data Standardization:** The company standardized customer data across more than 100 countries using Veeva OpenData and Veeva Network to support its Vault CRM migration and lay the foundation for scaling AI. * **HCP Engagement Scenario:** The example of an MSL/FSL entering a conversation unaware of the HCP's recent publication or conference speaking engagement highlights the current gap in customer knowledge that the 360-view aims to solve.
The Secret to a Perfect Broker-Partner Relationship
Self-Funded
@SelfFunded
Nov 25, 2025
This video provides an in-depth exploration of building strong, trust-based broker-partner relationships in the self-funded healthcare benefits industry, while also delving into broader themes of personal and professional development, particularly for women in leadership. The hosts, Cara Kirsch and Libby Henry, share their journey of forging a highly effective partnership, emphasizing radical transparency, integrity, and the ability to navigate difficult conversations. They illustrate how these principles led to significant cost savings for a client, transforming a 74% fully insured renewal into a self-funded plan that saved millions. The discussion progresses from the personal anecdotes of their initial "virtual lunch" meeting during COVID-19 to the professional strategies that underpin their success. Key themes include the importance of clear expectations, mutual respect, and a commitment to solving problems together rather than assigning blame. They highlight that the best partnerships are not solely driven by the lowest numbers on a spreadsheet but by unwavering trust, especially when challenges arise. The conversation also touches on the unique pressures faced by working mothers in high-powered careers, offering insights into balancing professional ambition with family life and the importance of instilling independence in children. Furthermore, the video shifts to a critical analysis of the self-funded healthcare market, advocating for employers to take greater control over their healthcare spending. Cara Kirsch recounts a pivotal experience where she challenged a 74% renewal increase for a client, ultimately saving them $3 million by implementing a reference-based pricing, self-funded plan. This case study underscores the power of education, transparency, and innovative financing mechanisms in an industry often plagued by misaligned incentives. The speakers also forecast future trends, anticipating increased financial strain on hospitals, a growing demand for transparency in claims management, and a continued bifurcation of the risk pool as more employers explore self-funding. They stress the fiduciary responsibility of employers under ERISA and the need for consultants to act as stewards of the craft, empowering clients with knowledge and options. Key Takeaways: * **Radical Transparency and Integrity in Partnerships:** The foundation of a strong business relationship lies in radical transparency, honesty, and integrity. Partners should be able to have difficult conversations without fear of damaging the relationship, fostering an environment where mistakes are owned, and solutions are sought collaboratively. * **Beyond the Spreadsheet Numbers:** The most effective partnerships are not solely based on the lowest price or "best deal" but on the ability to trust and rely on each other, especially when things go wrong. This long-term trust often leads to better outcomes than short-term cost-cutting. * **Clear Expectations and Mutual Respect:** Establishing clear expectations early in a partnership, even if it means initially turning down business that doesn't fit the established process, builds respect and long-term commitment. This allows for more frank and productive discussions later. * **Continuous Learning and Adaptability:** Successful professionals in the healthcare industry must be "stewards of the craft," continuously learning and adapting to rapid changes. It's crucial to be open to different approaches and learn from others, even if they don't align with one's initial methods. * **Fiduciary Responsibility for Employers (ERISA):** Employers, as plan sponsors, have a fiduciary responsibility under ERISA to use their employees' healthcare dollars appropriately and transparently. This mandates a proactive approach to understanding and managing healthcare benefits, not just accepting the status quo. * **Challenging the Status Quo in Healthcare Benefits:** Employers should challenge their consultants and carriers, especially when faced with exorbitant renewal increases. Innovative solutions like self-funded plans and reference-based pricing can provide power and control, leading to significant cost savings. * **Data-Driven Claims Management:** Self-funded plans offer greater visibility into claims data, enabling employers to understand the "how and why" of healthcare spending. This actionable information is crucial for implementing cost management tools and addressing issues like specialty drug costs and inpatient care. * **Misaligned Industry Incentives:** The current healthcare benefits industry often has misaligned incentives, where brokers and consultants may earn more as fully insured costs rise. Employers need to be aware of this and seek consultants who prioritize their clients' best interests and education over traditional commission structures. * **Managing Healthcare Cost Drivers:** Employers should focus on understanding and managing key cost drivers such as inpatient care and specialty drugs. Solutions exist in these areas, and employers should ensure their administrative partners support the implementation of these solutions. * **Bifurcation of the Risk Pool:** The healthcare market is likely to see a bifurcation of the risk pool, with employers willing to embrace self-funding and active management achieving better outcomes, while those reluctant to change face worsening risk pools and higher increases. * **Empowering Women in the Industry:** The video emphasizes the importance of women claiming their seat at the table in male-dominated industries like healthcare. It encourages male colleagues to support and defend women, and for women to mentor and empower younger generations to enter and succeed in these fields. * **Prioritizing Personal Well-being:** Balancing high-powered careers with personal life, especially motherhood, requires intentional prioritization and acknowledging that "balance" is often a myth. It's important to set boundaries, delegate, and make time for personal well-being without guilt. * **Instilling Independence in Children:** For working parents, fostering independence, problem-solving skills, and personal responsibility in children is a valuable outcome. This prepares them for adulthood and allows parents to manage their demanding careers more effectively. * **"Follow the Money" and "A Closed Mouth Doesn't Get Fed":** Employers are advised to "follow the money" in healthcare spending and to "ask more questions" until they fully understand the answers, even if they don't like them. This proactive questioning is essential for informed decision-making. **Tools/Resources Mentioned:** * **Paro Health:** Described as the largest benefits captive in the United States, making self-insurance simple and accessible for small to midsize employers and arming them with cost management tools. * **Nomi Health:** Positioned as a company that has rebuilt self-funded benefits from the ground up, offering solutions like no co-pays, no deductibles, and zero out-of-pocket costs for members. * **Claim Doc:** A medical claim auditing and member advocacy company providing fiduciary services to employer-sponsored benefit plans. * **Veilance:** An integrated ecosystem solution driven by data that manages and simplifies medical claim costs for self-insured employers. * **Gallagher:** Mentioned as having robust data, specifically regarding the 40% increase in cancer costs since 2020. **Examples/Case Studies:** * **74% Fully Insured Renewal to $3 Million Savings:** Cara Kirsch recounts a pivotal experience in 2017 where a home healthcare company faced a 74% increase on their fully insured plan. By developing a reference-based pricing and self-funded plan, she saved them $3 million over three years, demonstrating the power of challenging the status quo and innovative financing. * **Walmart and Mayo Clinic:** The example of Walmart requiring employees to go to Mayo Clinic for certain treatments is cited as a large employer strategy to control healthcare costs, suggesting that middle-market employers can explore similar solutions. * **Iowa Employment Conference Client:** Cara mentions that a group from the Iowa Employment Conference in 2024 became her client after 14 meetings and a year and a half, highlighting the long sales cycle and the importance of educating clients about their consulting agreements, compensation, and compliance.
Webinar- Predictive Intelligence - The Secret Weapon in Pharma BD Assessment with GSK, Veeva, Verix
Verix
/@verixAI
Nov 24, 2025
This webinar provides an in-depth exploration of how predictive intelligence and intelligent automation serve as a "secret weapon" in pharmaceutical Business Development (BD) assessments. Featuring perspectives from a strategic investor (GSK), a data provider (Veeva), and an analytics platform vendor (Verix), the discussion centers on transforming the complex, high-stakes process of evaluating M&A and licensing opportunities. The core challenge identified by Jacob Pajooki (GSK) is the need to integrate vast, disparate data sets—scientific, commercial, and financial—under immense time pressure and often with incomplete information, making BD assessments a blend of "art and science." The speakers emphasize that while data is foundational, the true value is realized by efficiently converting that data into actionable insights. Traditional BD processes often get stuck due to data silos (clinical, market, epidemiology), lack of a systematic framework, and difficulties in achieving stakeholder alignment. The solution presented leverages best-in-class data assets, specifically Veeva Compass Patient data, combined with Verix’s automated analytics platform, Tavana. This integration aims to provide a more robust, real-world informed opinion of an asset's potential, moving beyond high-level epidemiology reports to quantify the truly eligible patient population and understand the commercial effort required for launch. The Verix Tavana platform is introduced as a modular, automated solution designed to streamline the forecasting process, which is traditionally manual and time-consuming. The platform incorporates building blocks for landscape assessment, patient prediction, patient-based forecasting, SGA estimation, and Monte Carlo simulation. By automating these analytical tasks, the platform frees up human expertise to focus on less structured problems and critical judgment calls, thereby accelerating the time to decision-grade insights. The quantitative benefits highlighted include a 50% reduction in cost and cutting the assessment timeline from approximately six weeks to under one week, enabling unlimited assessments at a fixed cost. This approach ensures consistency and a data-driven basis for comparing competing opportunities, which is crucial for achieving rapid alignment among the large stakeholder teams typical of strategic investors like GSK. The discussion also delves into the critical role of granular, real-world data (RWD) in refining valuations. Jacob from GSK provided examples where detailed longitudinal patient data reveals roadblocks, such as high market inertia or a widely distributed patient population, which can significantly shrink the realistic market potential compared to initial scientific belief. Veeva Compass Patient data, characterized by its completeness, unlimited access, and daily updates, addresses these data limitations by providing anonymous longitudinal data encompassing prescriptions, procedures, and diagnoses, including visibility into previously blocked segments like specialty pharmacy and hospital/HCO settings. This timeliness and depth are essential for understanding the current state of the market and ensuring the valuation reflects the true scope of commercial investment needed for a near-term launch. ### Detailed Key Takeaways * **BD Assessments are High-Stakes and Complex:** Pharmaceutical BD assessments are high-stakes exercises involving billions of dollars, requiring a difficult blend of scientific rationale, commercial strategy, and precise timing, often conducted under pressure with incomplete information. * **The Need for Data Integration and Structure:** A major pain point is breaking down data silos (clinical, market, competitive landscape, epidemiology) and integrating them quickly. Implementing a systematic framework and disciplined approach to data sources is essential for scaling BD evaluation efforts. * **Automation Accelerates Decision-Making:** Leveraging advanced analytics and automation (like the Verix Tavana platform) converts manual forecasting and data sifting into streamlined, consistent processes, freeing up human experts to focus their judgment on critical, less-structured issues (e.g., IP, manufacturing, instinct). * **RWD Refines Market Potential:** Relying solely on high-level epidemiology data can lead to inaccurate forecasts. Robust, deep, and broad real-world data (RWD) is necessary to quantify the truly eligible patient population, understand patient distribution, and assess the commercial effort (field force size, investment) required for market penetration. * **Longitudinal Patient Data is Critical for Commercialization:** Tracking patient history and treatment cycles reveals market inertia and patient flow roadblocks. For late-stage assets (launching in 2-3 years), understanding these dynamics is crucial for accurately scoping the required commercial investment and balancing the Net Present Value (NPV) equation. * **Platform-Based Approach Drives Efficiency:** Utilizing a modular, platform-based solution (like Tavana) allows companies to conduct rapid evaluations, reducing the time to decision-grade insights from six weeks to under one week, demonstrating a significant ROI (50% cost reduction) and enabling unlimited assessments at a fixed cost. * **Data Timeliness is Essential for Valuation:** Daily data updates (as provided by Veeva Compass Patient) are critical for BD efforts, providing the most timely view of the market, allowing teams to see how the market is reacting to recent clinical or competitor activities and ensuring the valuation reflects the current state. * **Addressing Data Blind Spots:** Comprehensive data networks must include visibility into previously blocked segments, such as specialty pharmacy and hospital/HCO settings, to provide a full 360-degree view of the market dynamics and competitive landscape. * **The Role of AI is Supportive, Not Autonomous:** The advanced analytics platform operates on a "human-in-the-loop" model, combining human intelligence with machine learning. The platform provides a comprehensive, robust view of the market faster, informing the "go/no-go" decision and confidence level, rather than making autonomous decisions. * **Data Granularity Impacts Investment Assumptions:** Detailed, data-driven assessments often lead to a more realistic view of investment costs. While traditional approaches might be overly ambitious on forecasts and overly conservative on costs, granular data can rationalize lower investment costs, helping maintain a strong NPV. * **Supporting the Full Commercial Cycle:** Beyond BD, foundational patient data (like Veeva Compass Patient) supports other commercial use cases, including building triggers and alerts based on daily activity, and improving segmentation and targeting accuracy by providing a complete view of HCP and patient interactions. ### Tools/Resources Mentioned * **Veeva Compass Patient:** Anonymous patient longitudinal data network that includes prescriptions, procedures, and diagnoses. Noted for completeness, unlimited access, and daily updates, providing visibility into specialty pharmacy and hospital settings. * **Verix Tavana Platform:** An automated, modular platform for advanced analytics and predictive intelligence. Used to build fit-for-purpose tools for BD assessment, forecasting, and commercial operations. * **Veeva CRM:** Mentioned in the context of integrating triggers and alerts built off Compass Patient data. ### Key Concepts * **Predictive Intelligence:** The use of advanced analytics, machine learning, and automation to forecast future market conditions, patient behavior, and commercial potential of an asset, particularly within the context of BD assessments. * **Business Development (BD) Assessment:** High-stakes evaluation process in life sciences (M&A, licensing) that integrates scientific, commercial, and financial data to determine the value and viability of an asset. * **Net Present Value (NPV):** A financial metric used in BD to evaluate the profitability of an investment opportunity, calculated by balancing the expected future revenue (forecast) against the required investment (commercialization costs). * **Human-in-the-Loop (HITL):** An AI/ML approach where human expertise and judgment are integrated into the automated process. The technology provides robust data and insights, but the final decision-making authority remains with the human experts.
OpenStudyBuilder - Automating the Veeva EDC study setup
Katja Glass Consulting
/@katjaglassconsulting8982
Nov 24, 2025
This video provides an in-depth exploration of the initial steps in automating the Electronic Data Capture (EDC) study setup within Veeva systems, leveraging an open-source metadata repository called OpenStudyBuilder. The primary objective of this automation is to significantly reduce cycle times, align with the TransCelerate Digital Data Flow vision, and minimize manual tasks and potential human errors in clinical trial setup. The presentation details a proof-of-concept (PoC) implementation that serves as a foundation for a planned Veeva EDC integration release in 2026, emphasizing that while full automation is a future goal, the current PoC already delivers substantial benefits. The core of the automation process begins with the synchronization of the Case Report Form (CRF) library between OpenStudyBuilder and Veeva EDC. Currently, this synchronization is semi-automated, utilizing existing Veeva APIs. The process involves a translation script that extracts Veeva EDC library content, converts it into the ODM (Operational Data Model) format, and then populates the OpenStudyBuilder library by creating new forms. While SDTM (Study Data Tabulation Model) and other annotations are presently added manually, the video highlights ongoing efforts to finalize the CRF model and link activity instances to CRF items. A crucial second step involves maintaining alignment between the two libraries, for which a script is employed to identify and highlight differences, currently outputting a CSV file with plans for a future UI within OpenStudyBuilder. The video then moves to demonstrate the automation of the EDC study setup itself, again utilizing existing Veeva APIs. The automated tasks include the creation of study event groups and events based on OpenStudyBuilder's Schedule of Activities (SoA), the import of standard forms from the synchronized Veeva EDC library into the newly created trial, and the foundational setup of the study within Veeva EDC based on OpenStudyBuilder's operational data. It is noted that the study-level data collection module in OpenStudyBuilder is still under development, necessitating a workaround using Neo-Ash reports. This workaround facilitates the linking of activity instances, which represent CDISC (Clinical Data Interchange Standards Consortium) biomedical concepts, to specific CRF items. Following the selection of forms based on these activity instances, the automation sequence is initiated, culminating in the rapid population of content for the first draft of the study within Veeva. The presentation concludes by reiterating the vision for full automation once new Veeva API endpoints are released and OpenStudyBuilder's data collection module is finalized. Key Takeaways: * **Strategic Importance of Automation:** Automating the Veeva EDC study setup is critical for achieving significant gains in cycle time, reducing manual tasks, minimizing errors, and aligning with industry initiatives like the TransCelerate Digital Data Flow vision. * **Open-Source Metadata Repository:** OpenStudyBuilder serves as a central, open-source metadata repository and study metadata solution, providing the foundational data and structure necessary for automated EDC setup. * **Phased Automation Approach:** The current implementation is a proof-of-concept demonstrating semi-automated processes, with a clear roadmap towards full automation contingent on the release of new API endpoints and the finalization of specific modules within OpenStudyBuilder. * **CRF Library Synchronization:** A fundamental step in the automation is the robust synchronization of CRF libraries between OpenStudyBuilder and Veeva EDC, ensuring consistency and accuracy of data collection instruments across systems. * **Technical Workflow for Synchronization:** The synchronization process involves extracting Veeva EDC content via existing APIs, translating it into the ODM format, and then populating the OpenStudyBuilder library with new forms, highlighting the need for data transformation capabilities. * **Managing Library Alignment and Updates:** Ongoing management of CRF library alignment is crucial. A script is used to identify differences between the OpenStudyBuilder and Veeva EDC libraries, facilitating the implementation of necessary updates and maintaining data integrity. * **Specific Automated EDC Setup Tasks:** The PoC successfully automates key aspects of EDC study setup, including the creation of study event groups and events, importing standard forms from the synchronized library, and initiating the study structure within Veeva EDC. * **Leveraging Schedule of Activities (SoA):** The automation relies heavily on the Schedule of Activities defined within OpenStudyBuilder, which dictates the sequence and structure of events and forms within the clinical trial. * **Addressing Development Gaps with Workarounds:** The project demonstrates adaptability by implementing workarounds, such as using Neo-Ash reports, to bridge gaps where OpenStudyBuilder's study-level data collection module is still under development, ensuring progress despite ongoing development. * **Integration with Data Standards:** The process involves linking activity instances, which are implementations of CDISC biomedical concepts, to CRF items, underscoring the importance of adhering to industry data standards for interoperability and data quality. * **Future Vision for Full Automation:** The ultimate goal is complete automation of the EDC setup, which promises to further streamline clinical trial initiation and reduce the burden on clinical operations teams, once the necessary API enhancements and module developments are complete. Tools/Resources Mentioned: * **Veeva EDC:** The Electronic Data Capture system being automated. * **OpenStudyBuilder:** An open-source metadata repository and study metadata solution. * **Veeva APIs:** Application Programming Interfaces provided by Veeva, used for data extraction and system interaction. * **ODM Format:** Operational Data Model, an XML-based standard for exchanging clinical trial metadata and data. * **Neo-Ash Reports:** A specific reporting tool or system used as a workaround for an under-development module. Key Concepts: * **EDC (Electronic Data Capture):** A system used in clinical research to collect and manage patient data electronically, replacing traditional paper-based methods. * **CRF Library (Case Report Form Library):** A repository of standardized forms used for data collection in clinical trials, ensuring consistency across studies. * **Metadata Repository:** A centralized system for storing and managing metadata (data about data), crucial for defining and standardizing clinical trial elements. * **Schedule of Activities (SoA):** A detailed plan outlining all procedures, visits, and data collection points for each participant in a clinical trial. * **SDTM (Study Data Tabulation Model):** A standard developed by CDISC for organizing and formatting clinical trial data for submission to regulatory authorities. * **CDISC (Clinical Data Interchange Standards Consortium):** An organization that develops data standards to support the acquisition, exchange, submission, and archival of clinical research data and metadata. * **TransCelerate Digital Data Flow Vision:** An industry initiative aimed at improving the efficiency and effectiveness of clinical trials through digital transformation and seamless data exchange.
My Veeva Financial Insight: Growth, Risks & PBC Status
Corporate Decoder
/@CorporateDecoder
Nov 24, 2025
This video provides an in-depth financial analysis of Veeva Systems Incorporated's quarterly report (10-Q) for the period ending October 31, 2025. The "Corporate Decoder" channel aims to demystify corporate jargon and make SEC filings accessible, offering a detailed breakdown of Veeva's financial health, growth trajectory, risks, and unique status as a Public Benefit Corporation (PBC). The analysis progresses systematically through the key financial statements: the condensed consolidated balance sheets, statements of comprehensive income, statements of stockholders' equity, and statements of cash flows, before delving into the notes to the financial statements, management's discussion and analysis (MD&A), and risk factors. The speaker adopts a clear, explanatory approach, translating complex financial figures into understandable insights. They highlight Veeva's strong financial position, marked by substantial cash and short-term investments, and consistent growth in subscription services revenue, which is the core of their business. The analysis also covers operational expenses, profitability metrics like gross profit and operating income, and net income, demonstrating Veeva's increasing financial strength. A significant part of the discussion focuses on Veeva's strategic investments in R&D and sales & marketing, indicating a commitment to future growth and market expansion within the life sciences sector. Beyond the raw numbers, the video explores critical qualitative aspects that influence Veeva's performance and future outlook. This includes their reliance on third-party cloud infrastructure like AWS and Salesforce, the ongoing migration of customers to newer Vault CRM solutions, and the competitive landscape. A particularly unique aspect discussed is Veeva's status as a Public Benefit Corporation (PBC), which requires balancing shareholder interests with those of other stakeholders, potentially influencing long-term strategic decisions. The video concludes by summarizing Veeva's robust financial health, effective risk management, and clear strategy for continued growth, while also acknowledging the complexities and evolving nature of its PBC status. Key Takeaways: * **Strong Financial Liquidity and Investment Strategy:** Veeva boasts a substantial cash and cash equivalents position of $1.66 billion and over $4.97 billion in short-term investments as of October 31, 2025. This indicates strong operational cash generation and a wise treasury management strategy focused on earning returns, providing significant financial flexibility. * **Consistent Revenue Growth in Core Business:** Subscription services revenue, the primary driver, grew from $580 million to $682 million quarterly and from $1.67 billion to $1.97 billion for the nine months ending October 2025. This demonstrates robust demand for their cloud solutions in the life sciences industry. * **Healthy Profitability and Margins:** Total gross margin percentage remains strong at 75% for the quarter and 76% for the nine months, indicating efficient management of direct costs relative to revenue. Operating income also saw significant increases, reflecting improved core business profitability. * **Strategic Investment in R&D and Market Expansion:** Research and development expenses increased to $191 million quarterly and $568 million for the nine months, while sales and marketing expenses rose to $110 million quarterly and $318 million for the nine months. These investments signal a commitment to innovation and expanding market reach. * **Effective Cash Flow Generation:** Net cash provided by operating activities for the nine months was $1.3 billion, a healthy increase from $1.02 billion in the prior period. This confirms that Veeva's core operations are generating substantial cash, vital for funding business activities. * **Resolution of Major Legal Disputes:** The settlement of all ongoing litigations with Ivia in August 2025 is a significant positive development, removing a major uncertainty and potential financial overhang for the company. * **Public Benefit Corporation (PBC) Status:** Veeva's unique status as a PBC means its board must balance shareholder interests with those of other stakeholders (customers, employees, communities). This can lead to long-term strategic decisions that may not always maximize short-term shareholder profit but are intended for the company's sustained health and mission. * **Reliance on Third-Party Infrastructure:** A key risk factor is Veeva's dependence on third-party providers like Amazon Web Services and Salesforce for its cloud infrastructure. Any disruption from these providers could significantly impact Veeva's services and operations. * **Customer Migration Challenges:** The ongoing migration of customers from legacy Veeva CRM to newer Vault CRM solutions is a complex process with inherent risks, requiring careful management to ensure customer satisfaction and retention. * **Revenue Concentration Risk:** While common for B2B software companies, a concentration of revenue within a few key customers is a notable risk. The loss of even one major client could have a substantial impact on Veeva's financial performance. * **Industry-Specific Risks:** Veeva's heavy reliance on the life sciences industry makes it susceptible to changes within that sector, including drug pricing regulations, healthcare policy shifts, and industry consolidation. * **AI and Data Privacy Regulatory Risks:** The company acknowledges challenges and potential liabilities associated with evolving AI and data privacy regulations, which are particularly pertinent for a firm operating with sensitive life sciences data. * **Diversified Investment Portfolio:** Veeva's $4.97 billion short-term investment portfolio is well-diversified, primarily in corporate notes and bonds ($2.89 billion) and US Treasury securities ($1.26 billion), indicating a relatively safe investment strategy. * **Geographic and Product Revenue Breakdown:** North America accounts for approximately 60% of revenues, with Europe at 28%. Subscription services revenue is split almost evenly between Commercial Solutions and R&D Solutions, with R&D solutions revenue expected to grow, indicating a strategic shift or increased focus in this area. **Key Concepts:** * **10-Q Report:** A comprehensive quarterly financial report submitted by public companies to the U.S. Securities and Exchange Commission (SEC), providing a snapshot of their financial performance and position. * **Public Benefit Corporation (PBC):** A type of for-profit corporate entity that includes positive impact on society and the environment in addition to profit as its legally defined goals. * **Deferred Revenue:** Money received by a company for goods or services that have not yet been delivered or rendered. It is recorded as a liability until the service is performed or the product is delivered. * **Goodwill:** An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. It often represents the value of brand name, customer base, good customer relations, employee relations, and patents. * **Non-GAAP Measures:** Financial metrics that are not prepared in accordance with Generally Accepted Accounting Principles (GAAP). Companies often use them to provide an alternative view of their performance, excluding items like stock-based compensation or one-off charges. * **Fair Value Measurements (Level 2):** A classification for valuing assets and liabilities using observable market data for similar assets or liabilities, rather than quoted prices for identical assets (Level 1) or unobservable inputs (Level 3). **Examples/Case Studies:** * **Veeva's Financial Performance (Q3 2025):** The video uses Veeva's actual 10-Q filing for the period ending October 31, 2025, as a live case study, detailing specific figures such as $1.66 billion in cash, $4.97 billion in short-term investments, $682 million in quarterly subscription revenue, and a net income of $236 million for the quarter. * **Ivia Litigation Settlement:** The settlement of all ongoing litigations with Ivia in August 2025 is presented as a concrete example of how legal proceedings can impact a company's financial and operational outlook, and how their resolution can remove significant uncertainties.
Healthcare Costs Shut Government Down - Longest Shutdown in History Over ACA Premium Subsidies
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Nov 23, 2025
This video provides an in-depth exploration of the underlying causes of high healthcare costs in the United States, using the context of a government shutdown over Affordable Care Act (ACA) premium subsidies. Dr. Eric Bricker, the speaker, begins by highlighting that the longest government shutdown in US history was primarily due to disagreements between Democrats and Republicans regarding the continuation of ACA premium tax credits, which subsidize health insurance for 22 million Americans on individual exchange plans. He explains that these subsidies, expanded during the Biden administration, cost approximately $35 billion annually and aim to cap an individual's premium contribution at 8.5% of their income. The core of his argument is not to debate the policy itself, but to question why such massive subsidies are necessary due to exorbitant plan costs. To illustrate the problem, Dr. Bricker presents a direct comparison of ACA plan costs for a hypothetical family of five. In Dallas-Fort Worth, a Cigna bronze HMO plan with a $12,000 deductible costs $2,876 per month, totaling $34,512 annually. For a family earning $80,000, this necessitates a substantial government subsidy of $30,864 per year. He attributes these high costs in the traditional fee-for-service model to multiple layers of administration (insurance carrier and hospital), fee-for-service incentives that encourage more procedures, the burden of prior authorizations, and extensive billing and collections departments. He argues that this structure inflates costs far beyond the actual delivery of care. Conversely, Dr. Bricker compares this to a similar family in Los Angeles, where a Kaiser Permanente bronze HMO plan with an $11,600 deductible costs $1,723 per month, or $20,676 annually. This represents a staggering 40% reduction in cost compared to the Dallas-Fort Worth Cigna plan, despite Los Angeles having a higher cost of living. He attributes Kaiser's efficiency to its integrated model, where it functions as both the insurance company and the healthcare provider. This structure eliminates the need for separate administrations, removes fee-for-service incentives, bypasses prior authorizations, and significantly reduces billing complexities, as the provider directly bears the risk and manages care delivery. Dr. Bricker concludes by advocating for provider risk-bearing models, citing Steven Brill's book "America's Bitter Pill," which predicted the ACA's failure to control costs and recommended that providers take on risk, mirroring Kaiser's successful approach. He suggests that future ACA subsidies should exclusively go to risk-bearing providers, not traditional insurance companies, to achieve substantial cost savings. Key Takeaways: * **Healthcare Costs Drive Policy Disagreements:** Major government impasses, such as the longest US government shutdown, can stem directly from fundamental disagreements over healthcare costs and the funding of programs like ACA premium subsidies. * **ACA Subsidies are Substantial:** The Affordable Care Act's premium tax credits represent a significant annual expenditure (approximately $35 billion) to make health insurance affordable for millions, capping individual premiums at 8.5% of income. * **Traditional Healthcare Models are Inefficient:** The fee-for-service model, characterized by separate insurance carriers and providers, leads to inflated costs due to redundant administration, prior authorization processes, extensive billing departments, and incentives for providers to perform more services rather than focusing on cost-effective care. * **Integrated Systems Offer Significant Cost Savings:** Healthcare systems where the insurer and provider are combined into a single entity, such as Kaiser Permanente, demonstrate dramatically lower costs (e.g., 40% less in the example provided) compared to traditional models. * **Provider Risk-Bearing is Key to Efficiency:** When healthcare providers bear the financial risk for patient care (e.g., through capitated payments), it incentivizes them to streamline operations, reduce unnecessary procedures, and eliminate administrative overhead like prior authorizations and complex billing. * **Elimination of Fee-for-Service Incentives:** Integrated models remove the "do stuff, get paid" incentive inherent in fee-for-service, shifting the focus to efficient, value-based care delivery within a fixed budget. * **Reduced Administrative Burden:** Combining insurance and provider functions significantly reduces administrative duplication and the need for large departments dedicated to negotiating with and billing external entities. * **Proven Model for Decades:** The success of integrated systems like Kaiser Permanente, operating efficiently for decades with millions of satisfied members, demonstrates that lower-cost, high-quality healthcare is achievable within the US. * **Policy Recommendation for Cost Control:** A potential strategy for controlling healthcare costs and maximizing the impact of subsidies is to direct government support (like ACA subsidies) exclusively to healthcare providers who operate under a risk-bearing, capitated model, rather than to traditional insurance companies in a fee-for-service environment. * **Expert Endorsement:** The concept of providers bearing risk as a solution to healthcare cost control is supported by experts like Steven Brill, who extensively documented the creation of the ACA and concluded that its primary flaw was the absence of mechanisms to lower costs. Tools/Resources Mentioned: * **Health Sherpa.com:** A website mentioned as an easy way to shop for ACA health plans. * **"America's Bitter Pill" by Steven Brill:** A book that details the creation of the Affordable Care Act and advocates for provider risk-bearing models to control costs. * **AHealthcareZ.com:** The channel's website for more healthcare finance educational videos and Dr. Bricker's book. * **NBCNews.com & Reuters.com:** News sources cited for information on ACA subsidies and the government shutdown. Key Concepts: * **ACA (Affordable Care Act)/Obamacare:** US federal statute signed into law in 2010, aimed at reforming the healthcare system by expanding health insurance coverage. * **Premium Tax Credits/Subsidies:** Financial assistance provided by the government to help eligible individuals and families pay for health insurance premiums purchased through the ACA exchanges. * **Fee-for-Service:** A payment model where healthcare providers are paid for each service they provide, incentivizing more services. * **Integrated Health System:** A healthcare organization that combines health insurance functions with the delivery of healthcare services (e.g., hospitals, clinics, doctors) under a single entity. * **Provider Risk-Bearing:** A model where healthcare providers take on financial responsibility for the cost of care delivered to a patient population, often through capitation. * **Capitation:** A payment arrangement where a fixed payment is made to a healthcare provider for each enrolled person, regardless of the services provided, incentivizing cost-effective care. * **HMO (Health Maintenance Organization):** A type of health insurance plan that limits coverage to care from doctors who work for or contract with the HMO, typically requiring a primary care physician and referrals for specialists. * **Deductible:** The amount of money an individual must pay for healthcare services before their insurance plan starts to pay. * **Out-of-Pocket Max:** The maximum amount an individual will have to pay for covered healthcare services in a policy year, after which the insurance company pays 100% of the costs. Examples/Case Studies: * **Dallas-Fort Worth Cigna Bronze HMO Plan:** For a family of five with no subsidy, this plan costs $2,876/month ($34,512/year) with a $12,000 deductible and $21,200 out-of-pocket max. This example highlights the high cost of traditional fee-for-service models. * **Los Angeles Kaiser Permanente Bronze HMO Plan:** For the same family of five with no subsidy, this plan costs $1,723/month ($20,676/year) with an $11,600 deductible and $19,600 out-of-pocket max. This example demonstrates the significant cost savings (40% less) achieved through an integrated insurer-provider model.
Business boils down to 3 things | Chris Knerr
Made To See (formerly WebinarExperts)
/@madetoseemedia
Nov 22, 2025
This video features Chris Knerr, VP of Technology Strategy at Veeva Systems, who distills the complexities of business into three fundamental pillars that drive all company decisions and aspirations. Drawing from a diverse background spanning investment banking principles, Fortune 50 companies, and tech startups within the life sciences sector, Knerr argues that despite elaborate corporate rhetoric, every business objective ultimately aims at achieving growth, maintaining an efficient cost structure, or establishing quality differentiation in the market. He emphasizes that understanding these core drivers is paramount for anyone aspiring to senior leadership roles and for effectively securing investment or stakeholder buy-in. Knerr's perspective is rooted in a pragmatic, financially-focused approach, which he likens to the mindset required in investment banking. He posits that while various initiatives might be presented with different motivations, a critical analysis will always reveal an underlying connection to one of these three fundamental business imperatives. For instance, while employee satisfaction is desirable, it is not the primary driver for investment; rather, investors seek tangible financial returns. This direct, no-nonsense approach is encapsulated in his repeated emphasis on the phrase, "show me the money," highlighting the universal need to demonstrate clear financial value. The speaker's insights serve as a powerful decoder for corporate communication, encouraging listeners to look beyond jargon and identify the true financial implications of any proposed strategy or project. He suggests that this ability to articulate value in terms of growth, cost efficiency, or market differentiation is crucial for gaining traction with senior leadership and external investors. His extensive experience across Med Device, Pharma, and Consumer OTC industries further lends weight to these universal business truths, making them particularly relevant for professionals operating within the highly regulated and competitive life sciences ecosystem. Key Takeaways: * **Three Fundamental Business Pillars:** Chris Knerr identifies growth, an efficient cost structure, and quality (often manifesting as market differentiation) as the three core concerns that drive all business decisions and objectives. Any strategic initiative, regardless of its initial framing, ultimately seeks to impact one or more of these areas. * **Critical Financial Focus for Leadership:** Maintaining a keen financial focus is presented as a critical prerequisite for aspiring senior leaders. Knerr's background, which he likens to investment banking, underscores the importance of understanding the monetary implications of business actions. * **Decoding Corporate Jargon:** The video provides a framework for deconstructing complex corporate language. Knerr suggests that by decoding what companies "really care about," one can consistently trace back stated goals to one of the three fundamental pillars: growth, cost efficiency, or quality/differentiation. * **"Show Me The Money" Principle:** A central tenet is the necessity of demonstrating tangible financial returns or benefits to secure investment or buy-in. Knerr explicitly states that investors are primarily motivated by making money, and proposals must clearly articulate how they contribute to this goal, rather than focusing on secondary benefits like team happiness. * **Universality Across Business Contexts:** Knerr's experience spans Fortune 50 companies, management consulting, portfolio companies, and tech startups, indicating that these three core business drivers are universally applicable across diverse organizational structures and stages of development. * **Strategic Communication of Value:** For consultants and solution providers like IntuitionLabs.ai, this insight is crucial for effectively communicating the value proposition of their services. Framing AI solutions, Veeva CRM consulting, or data engineering in terms of how they drive client growth, reduce operational costs, or enhance regulatory compliance and differentiation will resonate more strongly with decision-makers. * **Understanding Client Motivations:** Companies in the pharmaceutical and life sciences sectors, IntuitionLabs.ai's target market, are inherently driven by these same financial imperatives. Solutions that can clearly demonstrate impact on commercial operations (growth), clinical data management (efficiency, quality), or regulatory adherence (quality, differentiation) will be highly valued. * **Quality as Differentiation:** Knerr's inclusion of "quality" as a core pillar, which he also equates with differentiation, is particularly relevant for regulated industries. For IntuitionLabs.ai, this means emphasizing how their AI-powered solutions streamline compliance tracking, automate audit trails, and manage GxP/21 CFR Part 11 requirements, thereby enhancing quality and providing a competitive edge. Key Concepts: * **Growth:** The expansion of a company's market share, revenue, customer base, or overall business operations. * **Efficient Cost Structure:** The optimization of operational expenses and resource allocation to maximize profitability and reduce waste. * **Quality/Differentiation:** The provision of superior products, services, or operational standards that set a company apart from its competitors, often including adherence to high regulatory and compliance standards in the life sciences. * **Financial Focus:** A strategic mindset that prioritizes and articulates business value primarily in monetary terms, demonstrating clear return on investment (ROI). * **Show Me The Money:** A direct and pragmatic demand for evidence of tangible financial returns or benefits as the basis for investment or approval.
VEEV Veeva Systems: Q3 Beat But Stock Drops - 5 Price Targets & Friday Predicted Opening? 📉
StockInvest.us
/@StockInvestUS
Nov 20, 2025
This video provides an in-depth exploration of Veeva Systems Inc. (VEEV) stock performance, offering a detailed analysis of its recent trading activity, financial results, technical indicators, and future price predictions. The analysis, published on stockinvest.us, categorizes VEEV as a "hold or accumulate" based on its system's assessment as of November 20, 2025. The presentation progresses from an overview of the stock's current status to a granular examination of its historical fluctuations, Q3 earnings report, various technical signals, analyst ratings, and insider trading patterns, concluding with projected price movements and risk assessment. The video highlights a paradoxical situation where Veeva Systems reported strong fiscal third-quarter results, with total revenue increasing 16% year-over-year to $811.2 million and subscription services revenue rising 17% to $682.5 million. Despite this robust performance, the stock experienced a decline after market close, indicating investor disappointment likely stemming from guidance details, profitability concerns, or high expectations already built into the stock price. This sell-off is anticipated to lead to increased short-term volatility as traders evaluate recurring revenue growth against any weaknesses in margins or future outlook. Further into the analysis, the video delves into both technical and fundamental aspects. Technically, VEEV shows several negative signals, including sell signals from both short-term and long-term moving averages, a general sell signal from the relationship between these averages, and a sell signal from a pivot top identified 32 days prior. The 3-month Moving Average Convergence Divergence (MACD) also indicates a sell signal. However, a rare "golden star" signal was identified in the long-term chart on January 17, 2025, suggesting potential for significant and sustained gains. Fundamentally, while revenue growth is strong, analysts have assigned a general neutral rating, with "strong sell" ratings for the price-to-earnings (PE) and price-to-book (PB) ratios, but a "strong buy" for return on investment. Insider trading activity shows a net negative trend, with more shares sold than purchased in the last 100 trades. The analysis projects a potential change of approximately 4.11% over the next three months, with a possible return ranging from 4.11% to 20.23%. For the longer term, a 12-month analysis indicates a projected change of 38.73%, placing the future price between $365.55 and $440.63. The stock finds support at $270.06, which could present a buying opportunity, and faces resistance at $272.33 and $290.44. The risk associated with VEEV is considered medium due to its average daily movements and favorable trading volume. The video concludes by reiterating the "hold or accumulate" recommendation, emphasizing the importance of monitoring guidance and margin trends as key catalysts for future price movements. Key Takeaways: * **Current Stock Recommendation:** As of November 20, 2025, Veeva Systems (VEEV) is categorized as a "hold or accumulate" by stockinvest.us, with a score of 0.85, suggesting it might be wise to hold existing shares or consider accumulating more while monitoring developments. * **Q3 Performance vs. Stock Reaction:** Veeva reported strong fiscal Q3 results with total revenue up 16% year-over-year to $811.2 million and subscription services revenue up 17% to $682.5 million. Despite this beat, the stock declined, indicating investor disappointment likely due to guidance details, profitability concerns, or high expectations. * **Short-Term Price Prediction:** The 3-month trend suggests a potential change of approximately 4.11%, with a possible return ranging from 4.11% to 20.23%. * **Long-Term Price Prediction:** The 12-month analysis projects a change of 38.73%, with the stock's future price potentially ranging from $365.55 to $440.63. * **Technical Sell Signals:** The stock shows multiple sell signals from short-term and long-term moving averages, their relationship, a pivot top identified 32 days ago, and the 3-month MACD, indicating a generally negative technical outlook. * **Rare "Golden Star" Buy Signal:** A unique "golden star" signal was identified in the long-term chart on January 17, 2025. This rare occurrence, where short-term moving average, long-term moving average, and price line converge, is often followed by significant and sustained gains. * **Analyst Sentiment:** Analysts have assigned VEEV a general neutral rating. While they rate the price-to-earnings (PE) and price-to-book (PB) ratios as "strong sell," the return on investment (ROI) is rated as a "strong buy." * **Insider Trading Activity:** Recent insider trades show a net negative "insider power" ratio of -26.467, with insiders selling more shares (108,337) than purchasing (61,29) in the last 100 trades. * **Support and Resistance Levels:** The stock finds support at $270.06, which could be a buying opportunity. Resistance levels are identified at $272.33 and $290.44, with a breakout above these potentially triggering buy signals. * **Risk Assessment:** VEEV is considered to have a medium level of risk due to its average daily price fluctuations and favorable trading volume. A recommended stop loss is set at $255.78, reflecting a 5.44% decrease. * **Importance of Guidance and Margins:** For long-term investors, monitoring management's guidance and margin trends will be crucial in determining whether the recent pullback represents a buying opportunity or a shift towards a prolonged rerating. * **Anticipated Opening Price:** For the next trading day (Friday, November 21), VEEV is anticipated to open at a higher price, increasing by $1.97, with an expected trading price of $272.47. * **Disclaimer on Financial Advice:** The video explicitly states that its content is for informational purposes only and should not be considered financial advice, emphasizing the high risk involved in trading and the need to consult a financial advisor. Tools/Resources Mentioned: * **stockinvest.us:** The website providing the stock analysis and predictions. * **AI stock analysis tool powered by GPT4:** A newly launched tool by stockinvest.us for enhanced trading decisions, offering free price predictions and deep analysis for 45,000 companies. Key Concepts: * **Price-to-Earnings (PE) Ratio:** A valuation metric comparing a company's current share price to its earnings per share. A high PE ratio can suggest overvaluation or anticipated future growth. * **Pivot Top:** A technical analysis pattern indicating a potential reversal from an uptrend to a downtrend, signaling a sell opportunity. * **Golden Star Signal:** A rare technical signal occurring when the short-term moving average, long-term moving average, and the price line converge in a unique combination, often preceding significant and sustained stock gains. * **Moving Average Convergence Divergence (MACD):** A trend-following momentum indicator that shows the relationship between two moving averages of a security's price. A sell signal from MACD typically indicates bearish momentum. * **Moving Averages (Short-term and Long-term):** Technical indicators that smooth out price data to identify trends. Their crossovers and relationships often generate buy or sell signals. * **Support and Resistance Levels:** Price levels on a chart where the price tends to stop and reverse. Support is a price level where demand is strong enough to prevent the price from falling further, while resistance is a level where supply is strong enough to prevent the price from rising further. * **Insider Power:** A metric used to gauge the sentiment of company insiders (executives, directors) regarding their own stock, calculated from their buying and selling activities. A negative ratio indicates more selling than buying.
$VEEV Veeva Systems Q3 2026 Earnings Conference Call
EARNMOAR
/@EarnMoar
Nov 20, 2025
This video provides an in-depth exploration of Veeva Systems' fiscal 2026 third-quarter financial results and strategic initiatives, as discussed during their earnings conference call. The call, primarily a Q&A session with CEO Peter Gastner, EVP Strategy Paul Shawa, and CFO Brian Van Wagner, highlights Veeva's strong performance with total revenue of $811 million and non-GAAP operating income of $365 million, exceeding guidance. A central theme is the significant progress and potential of "Veeva AI," which is positioned as a major initiative for customers, the industry, and Veeva itself. The discussion also covers innovation across all product areas, including Vault CRM, Crossix, clinical, and safety solutions. The conversation delves deeply into the ongoing migration of top 20 pharmaceutical customers to Vault CRM, noting that 14 are expected to migrate, with six potentially opting for other solutions. While acknowledging potential revenue at risk, Veeva emphasizes the multi-year nature of these projects and the overall health of its CRM business, which now constitutes about 20% of total revenue, down from 25% two years prior due to growth in other product areas. The company expresses confidence in retaining customers and the potential for "win-backs," driven by the integrated value proposition of the broader CRM suite, including new add-ons like Service Center, Marketing Automation, and Patient CRM. Veeva's strategy for smaller customers, who prefer integrated solutions over custom builds, is also highlighted. Beyond CRM, the call explores Veeva's R&D (Development Cloud) and Quality Cloud segments. In R&D, discussions include the competitive landscape in the Electronic Data Capture (EDC) market, the importance of integrated solutions for clinical operations and data, and future innovations aimed at bridging sponsors with clinical research sites and improving patient recruitment. Safety systems are identified as a significant opportunity, particularly with AI, despite long sales cycles and the inherent complexity of global drug safety. The Quality Cloud is noted for its expanding market reach, including CDMOs and manufacturing plants, driven by its unique platform approach encompassing quality documentation, quality management systems (QMS), and GxP training, with new products like batch release, computer systems validation, and Laboratory Information Management Systems (LIMS) showing promise. The company also touches on the positive impact of its partnership with IQVIA, enhancing interoperability and customer confidence across commercial and clinical domains, and the strategic importance of its "Veeva Basics" offering for small biotechs. Key Takeaways: * **Strong Financial Performance:** Veeva reported excellent Q3 2026 results with $811 million in total revenue and $365 million in non-GAAP operating income, surpassing guidance, indicating robust execution across the business. * **Veeva AI as a Strategic Pillar:** AI is a major initiative, with significant progress expected to deliver practical, value-adding, industry-specific solutions for customers, particularly in automating tasks like insight generation in CRM, increasing efficiency in safety case processing, and streamlining clinical operations. * **Vault CRM Migration Dynamics:** 14 of the top 20 customers are expected to migrate to Vault CRM, with 6 potentially choosing other solutions. While this presents some revenue risk, it's considered a multi-year transition with no material impact expected in the short term, and Veeva anticipates win-backs and continued growth from its broader customer base. * **CRM Business Evolution:** CRM now accounts for approximately 20% of Veeva's total revenue, down from 25% two years ago, reflecting the diversification and growth of other product areas. The overall CRM business remains healthy, particularly with smaller customers who prefer integrated solutions. * **Integrated Commercial Cloud Strategy:** Veeva is building a comprehensive "industry cloud" for life sciences, connecting CRM, commercial content, Crossix, and data assets on a common platform. This integration aims to provide significant competitive advantage and synergy for customers. * **R&D Cloud Momentum:** Veeva continues to see strong momentum in its Development Cloud, with 20 out of the top 20 customers having selected their ETMF solution. Future innovations in clinical, safety, and quality are expected to drive efficiency and address complex industry needs. * **Safety Systems as a High-Potential Area:** Veeva Safety is a complex but high-potential area, with AI expected to drive faster adoption by reducing labor and improving efficiency in adverse event processing. The company's eight-year investment in this area creates a significant competitive moat. * **Crossix as a Growth Driver:** Crossix continues to be a strong growth driver, benefiting from increased digital marketing spend in the life sciences, the growing importance of measurement and optimization, and its expanding role as an industry standard. * **Healthy Pharma Macro Environment:** The pharmaceutical industry remains healthy, with steady demand driven by ongoing scientific evolution and the need to address uncured diseases, leading to no material changes in customer buying behaviors. * **Strategic Role of Business Consulting:** Veeva's integrated approach combines software, data, and consulting services, positioning the company as a "general contractor" for life sciences. Business consulting plays a critical role in change management and driving broader platform adoption. * **AI Monetization Across Segments:** AI's value is expected to be broadly even across commercial and R&D, with implementations focusing on insight generation and agility in commercial, and labor reduction in areas like safety and clinical operations. * **Veeva Basics for Small Biotechs:** The Veeva Basics offering, with over 100 customers, supports the smaller end of the life sciences industry, providing professional solutions that allow companies to scale to enterprise Veeva without changing systems, fostering overall industry growth. * **Long-Term Vision and Competitive Advantage:** Veeva's long-term commitment to life sciences, its integrated platform approach, and continuous innovation (especially with AI) are seen as key competitive advantages against competitors who may offer less comprehensive or industry-specific solutions. **Tools/Resources Mentioned:** * Veeva Vault CRM Suite * Veeva Medical * Veeva PromoMats * Veeva Crossix * Veeva OpenData * Veeva Link * Veeva Compass * Veeva CRM Pulse * Veeva Clinical Platform * Veeva Clinical Data Management * Veeva Safety * Veeva RIM (Regulatory Information Management) * Veeva Quality Cloud (Quality Documentation, QMS, GxP Training, Batch Release, Computer Systems Validation, LIMS) * Veeva Basics * Salesforce.com (as a platform/competitor for CRM) * AWS (Amazon Web Services) * Microsoft (as a partner for AI) * Anthropic (as a partner for AI) * IQVIA (strategic partner) * Doximity (digital avenue for HCPs) * Open Evidence (digital avenue for HCPs) **Key Concepts:** * **Veeva AI:** Veeva's overarching initiative to embed artificial intelligence, including Large Language Models (LLMs) and AI agents, across its product suite for intelligent automation and insight generation. * **Industry Cloud:** Veeva's strategy to provide a comprehensive, integrated suite of software, data, and consulting services tailored specifically for the life sciences industry. * **Vault CRM:** Veeva's next-generation CRM platform, designed to replace its legacy Salesforce-based CRM, offering deeper integration with other Veeva Vault applications. * **Development Cloud:** Veeva's suite of applications for R&D, including clinical operations, clinical data management, safety, and regulatory information management. * **Quality Cloud:** Veeva's solutions for quality management, including documentation, QMS, GxP training, and manufacturing quality control. * **ETMF (Electronic Trial Master File):** A system for managing and storing essential clinical trial documents. * **EDC (Electronic Data Capture):** Software used in clinical trials to collect and manage patient data. * **RTSM (Randomization and Trial Supply Management):** Systems for managing patient randomization and drug supply in clinical trials. * **Ecoa (Electronic Clinical Outcome Assessment):** Digital tools for collecting patient-reported outcomes in clinical trials. * **LIMS (Laboratory Information Management System):** Software for managing laboratory samples, experiments, and results, particularly in manufacturing quality control. * **GxP:** A set of good practice guidelines (e.g., Good Manufacturing Practice, Good Clinical Practice) for regulated industries. * **21 CFR Part 11:** FDA regulations on electronic records and electronic signatures. * **Probabilistic Computing:** An AI concept related to making predictions or decisions based on probabilities, often in the context of LLMs. **Examples/Case Studies:** * **Top 20 CRM Migrations:** Discussion centered on the migration status of the top 20 pharmaceutical companies to Veeva's Vault CRM, with 14 committed and 6 undecided or opting for alternatives, highlighting the strategic importance of these large clients. * **EDC Customer Win-Back:** A specific instance where a top 20 customer decided to revert to a previous EDC provider, which Veeva characterized as an "aberration" rather than a trend, emphasizing its strong pipeline and integrated solution approach. * **LIMS Early Adopter:** Mention of the first early adopter in the top 20 for Veeva's LIMS product for two manufacturing sites, signaling entry into a new, significant market segment within quality. * **IQVIA Partnership:** The strategic partnership with IQVIA was cited as a positive macro-level trend, improving interoperability and customer confidence for joint clients across commercial and clinical operations.
Interview with Veeva Manny Vazquez
Moe Alsumidaie
/@Annexclinical
Nov 20, 2025
This video provides an in-depth exploration of the evolving landscape of clinical data management, particularly in the context of emerging AI technologies and the declining centrality of traditional Electronic Data Capture (EDC) systems. Featuring Manny Vazquez, Senior Director of Clinical Data Strategy at Veeva, the discussion challenges the status quo of fragmented tech stacks in clinical trials, advocating for a platform-centric approach to achieve greater efficiency and scalability across the life sciences. The conversation underscores the urgent need for pharmaceutical companies to rethink their data infrastructure to become "AI-ready" rather than relying on outdated, inefficient workarounds. Vazquez highlights that many companies, led by long-tenured leadership, have accumulated a "cluster" of custom solutions layered on top of existing systems over decades. While these solutions were once considered "best-of-breed" at the time of their implementation, they have collectively resulted in wholly inefficient processes. He argues that the industry is at a critical turning point, driven primarily by the advent of AI, which is not merely an evolution but a "completely new computing paradigm." This shift necessitates a fundamental reset, forcing organizations to critically examine their processes and data foundations, as being "AI-ready" is paramount for future success and avoiding significant competitive catch-up. The discussion further clarifies that the push for simplicity in clinical data management does not imply reducing the volume or complexity of data collected. Instead, the focus is on simplifying the *processes* by which data is collected, processed, and moved through the pipeline. Vazquez emphasizes that stacking complexity on top of existing complexity is unsustainable, especially with the increasing volume of data from diverse sources. The goal is to enhance user experience, leverage better tools, and prioritize configuration over extensive customization, ensuring that the underlying content and data remain robust while interactions with them become more streamlined. A significant portion of the interview is dedicated to outlining the practical foundation required for AI implementation. Vazquez explains that for AI to function effectively, companies need all their data in one centralized repository, accessible at a steady, high frequency. He cites Veeva's own product, CDB (Clinical Data Backbone), and the Study File Format API as examples of solutions designed to meet these foundational needs. He argues that EDC is no longer the "center of the universe" but merely one of many data sources, with tools like CDB serving as the new "data workbench" hub. This shift is crucial for addressing the pervasive issue of data fragmentation, which currently leads to immense waste in manual data review and inefficient third-party data reconciliation, especially as clinical trials integrate data from wearables, real-world evidence, and genomics. Key Takeaways: * **Outdated Tech Stacks and Inefficiency:** Many pharmaceutical companies operate with inefficient tech stacks built over decades, characterized by layered custom solutions that create a "cluster" rather than a cohesive system. This leads to significant waste in manual data review and reconciliation. * **Platform Approach for Automation:** There's a critical need to transition from a "best-of-breed" tool mentality to a "platform approach" across life sciences to achieve end-to-end automation and scale, breaking the cycle of inefficiency. * **AI as a Paradigm Shift:** AI represents a "completely new computing paradigm," not just an evolution. It demands a fundamental re-evaluation of existing processes and data infrastructure, making "AI-readiness" an immediate imperative. * **Data as AI's Foundation:** Successful AI implementation hinges on having structured, organized data in a unified repository (or multiple accessible repositories). Without this foundational data layer, AI cannot be effectively deployed. * **Simplifying Processes, Not Data Volume:** The goal is to simplify the *processes* of data collection, processing, and movement, not to reduce the volume or underlying complexity of the data itself. This requires better tools, user experience, and configuration over customization. * **Practical AI Foundation:** Preparing for AI involves two key steps: consolidating all relevant data into a single, accessible location (e.g., a data workbench like Veeva's CDB) and ensuring high-frequency access to that data (e.g., via APIs like Veeva's Study File Format API). * **EDC's Diminished Role:** Traditional EDC systems are no longer the central hub of clinical data management. They are now just one of many data sources, alongside wearables, eCOAs, EMRs, and real-world evidence. * **Data Workbenches as the New Hub:** Tools like Veeva's CDB, functioning as a "data workbench," are emerging as the new central hub for ingesting, harmonizing, and managing diverse data sources in clinical trials. * **Combating Data Fragmentation:** Fragmentation remains a major risk, especially with the integration of new technologies like wearables and implantable devices. Automated ingestion and harmonization into a single database are crucial to overcome manual, inefficient reconciliation. * **Value of All Data:** While protocols may define specific data points for endpoints, all collected data, including massive volumes from wearables, will eventually be valuable for advanced analytics and AI-driven investigations. * **Avoid Complacency:** A significant mistake organizations make is not actively preparing for AI or assuming their current infrastructure is an adequate foundation for layering AI solutions. The "sprint has started," and immediate investment in foundational data strategies is necessary. Tools/Resources Mentioned: * **Veeva CDB (Clinical Data Backbone):** A product designed to consolidate all clinical trial data into one place. * **Veeva Study File Format API:** An API built to provide steady, high-frequency access to consolidated data for analytics and AI. * **EDC (Electronic Data Capture):** Traditional systems for capturing clinical trial data, now seen as one of many data sources. * **ChatGPT:** Mentioned as the catalyst that accelerated the AI hype cycle and highlighted its immediate arrival. Key Concepts: * **AI-Ready:** The state of an organization having the necessary data infrastructure, processes, and technological foundation to effectively implement and leverage Artificial Intelligence. * **Platform Approach:** A strategy where an integrated suite of tools and services (a platform) is used to manage end-to-end processes, rather than relying on disparate "best-of-breed" solutions that require extensive custom integrations. * **Data Fragmentation:** The issue of clinical trial data being scattered across multiple, disconnected systems and repositories, leading to inefficiencies in access, harmonization, and analysis. * **Data Harmonization:** The process of standardizing data from various sources into a consistent format and structure, making it compatible for analysis and integration. * **Data Workbench:** A centralized environment or tool (like Veeva CDB) that allows users to ingest, manage, process, and analyze diverse datasets from multiple sources. * **eCOA (electronic Clinical Outcome Assessment):** Electronic methods for patients to report outcomes. * **EMR (Electronic Medical Record):** Digital versions of patient charts from healthcare providers. * **Real-World Evidence (RWE):** Clinical evidence derived from sources outside of traditional randomized controlled trials, such as electronic health records, claims data, and patient registries. * **Genomics Data:** Information derived from the study of an organism's entire set of DNA.
Veeva Commercial Summit: On AI, content, and MLR Review with Emma Hyland
pharmaphorum media limited
/@Pharmaphorum
Nov 19, 2025
This video provides an in-depth exploration of how Artificial Intelligence (AI) is transforming content strategy and the Medical, Legal, and Regulatory (MLR) review process within the life sciences industry, as discussed at the Veeva Commercial Summit 2025. Emma Hyland, Veeva's Vice President of Commercial Content Strategy for Europe, highlights the urgent need to revolutionize the MLR role due to accelerating product launches and evolving healthcare professional (HCP) content preferences. While AI promises to significantly accelerate content delivery, improve quality, and reduce MLR team workload, its true value is realized when integrated into a larger strategy to reimagine end-to-end content operations, allowing leading biopharma companies to deliver more tailored and customer-centric content while maintaining compliance. Hyland details the industry's current adaptation to AI, noting that approximately 80% of Veeva's customers have engaged in pilot experimentation over the past 12-18 months, often with mixed results. Common reasons for pilot failures include difficulties in scaling solutions across multiple markets or brands due to complexity and subjectivity, poor user experience leading to low adoption, and a misdirected focus on simply weaving AI into existing processes rather than fundamentally rethinking productivity. Many initial attempts generated "noise" and extra work, counteracting the goal of faster, better content. Veeva's strategy, in contrast, emphasizes embedding generative AI into its Vault platform to build specific, user-friendly agents that simplify complex tasks. The highest opportunity for AI in content, according to Hyland, lies within the MLR space, which she describes as "ripe for disruption" after years of minimal change. The shift is from viewing MLR as merely a "complaint avoidance tool" to a competitive differentiator that enables rapid delivery of accurate, scientifically correct, and patient-appropriate content. Veeva announced two MLR-focused agents for release in December 2025: a "quick check agent" to assess content quality before MLR submission, and a "promat assistant" offering a conversational interface for interrogation and questioning. Future innovations include a "claims agent" and persona-based agents tailored for medical, legal, and regulatory reviewers, providing specialized support for each role. Despite the technological advancements, insights from customer focus groups and the summit underscore that success hinges not just on technology, but critically on "people and process," as exemplified by Moderna, Veeva's first global AI customer. The long-term vision for MLR sees AI significantly increasing efficiency and managing rising content volumes driven by personalization, while human accountability for content sign-off remains paramount due to regulatory requirements and patient safety. Key Takeaways: * **MLR Process is Ripe for AI Disruption:** The Medical, Legal, and Regulatory (MLR) review process in life sciences is identified as the area with the highest opportunity for AI transformation, having seen little significant change in many years, making it ready for innovation. * **AI for Competitive Advantage in MLR:** The industry is shifting its perception of MLR from a compliance gatekeeper (complaint avoidance) to a strategic tool that provides a competitive edge by enabling faster delivery of high-quality, accurate, and scientifically correct content to market. * **Challenges in Early AI Pilots:** Many initial AI pilots in life sciences have failed due to difficulties in scaling solutions across enterprise organizations, high complexity and subjectivity, poor user experience leading to low adoption, and a misdirected focus on simply integrating AI into existing processes rather than reimagining productivity. * **Veeva's AI Strategy with Agents:** Veeva's approach involves embedding generative AI into its Vault platform to create specialized "agents" designed to perform specific tasks. This aims to simplify AI utilization and integrate it seamlessly into daily workflows. * **Specific AI Agents for MLR:** Veeva announced two key MLR-focused agents: a "quick check agent" for pre-submission content quality assessment and a "promat assistant" providing a conversational interface for content interrogation. These are designed to streamline and enhance the review process. * **Future AI Innovations:** Beyond initial MLR agents, Veeva plans to introduce a "claims agent" to manage the complex area of claims, followed by "persona-based agents" tailored for specific medical, legal, and regulatory reviewers, providing targeted support for individual roles. * **Beyond Technology: People and Process are Key:** While AI technology is exciting, the ultimate success of AI implementation in life sciences hinges on getting the "people and process" right. This foundational principle, often overlooked in the excitement of new tech, remains crucial for successful transformation. * **Human Accountability Remains Paramount:** Despite AI's capabilities, human accountability for signing off every piece of content before it reaches patients and HCPs will remain in the near to mid-term future due to regulatory requirements and the critical importance of patient safety. AI will augment, not replace, human reviewers. * **AI to Manage Content Volume and Personalization:** As content volumes continue to rise due to the demand for personalized content, AI will be essential for creating more efficient ways to manage this influx, enabling the industry to achieve its personalization goals without proportional increases in human resources. * **Partnership for Industry-Wide Solutions:** Customer focus groups indicate a strong desire to partner with solution providers like Veeva to build industry-wide solutions, suggesting a collaborative approach is valued for developing scalable and impactful AI tools. Tools/Resources Mentioned: * **Veeva CRM:** A leading platform in the pharmaceutical industry, central to the discussion of commercial operations. * **Veeva Vault Platform:** The foundational platform where Veeva is embedding generative AI to build specific agents. * **Quick Check Agent (Veeva AI):** An AI agent designed to check content quality before submission into the MLR process. * **Promat Assistant (Veeva AI):** A conversational AI interface for interrogating and asking questions about content. * **Claims Agent (Veeva AI):** A planned future AI agent focused on managing claims. * **Persona Based Agents (Veeva AI):** Planned future AI agents tailored for medical, legal, and regulatory reviewers. Examples/Case Studies: * **Moderna:** Cited as Veeva's first global AI customer, sharing their implementation experience and demonstrating the importance of integrating technology with people and process.
The Death Of The Broker, And The Rise of the Strategic Consultant
Self-Funded
@SelfFunded
Nov 18, 2025
This video provides an in-depth exploration of the evolving landscape of the employee benefits industry, moving from traditional transactional brokering to strategic consulting. Featuring Trey Halbert, CEO of ExperINS, an employee benefits agency, the discussion centers on the inherent "brokenness" of the healthcare system and how strategic consultants can make a profound impact by aligning health plans with a company's core business strategy and C-suite objectives, rather than merely focusing on HR-level administration. Halbert emphasizes a "strategy first benefits, people first service" approach, highlighting the importance of understanding a client's mission, vision, and values to craft a benefits program that supports their overall business goals. The conversation delves into the operational framework of ExperINS, detailing its founding principles, cultural values (such as "no a**holes," "elevate awesomeness," and "advocate relentlessly"), and the strategic decision to leverage peer networks like the True Network of Advisors. This network provides crucial resources, best practices, and collaborative opportunities that enable smaller firms to compete effectively and deliver innovative solutions at scale. A significant portion of the discussion is dedicated to the financial implications of benefits, illustrating how optimized health plans can directly enhance business valuation and reframing self-funding as a strategic financing decision rather than just a risk. Crucially, the video explores the role of innovation, particularly "Agentic AI," in transforming the consulting profession. Halbert envisions AI automating menial, data-intensive tasks like RFP processing, data extraction, and "quote-to-card" workflows. This automation, he argues, will free up human consultants to focus on high-level strategic thinking, complex problem-solving, and truly bending the cost curve of healthcare. The discussion also touches on various cost-saving and member-empowering solutions, including high-performance networks, reference-based pricing, virtual healthcare platforms for mental health, and international prescription drug sourcing, all aimed at improving access, affordability, and transparency in a complex system. Key Takeaways: * **Evolution to Strategic Consulting:** The employee benefits industry is shifting from transactional brokering to strategic consulting, where advisors align health plans with C-suite business objectives and overall company strategy, not just HR needs. This involves understanding an employer's mission, vision, and values. * **Consultants' Indispensable Value:** The inherent complexity, obfuscation, and proprietary nature of healthcare contracts make strategic consultants critical for employers to navigate the system, optimize health plan performance, and make informed decisions. * **Culture as a Differentiator:** Building a strong internal culture, defined by core values like "no a**holes," "get done and have fun," "elevate awesomeness," "leave a ladder," and "advocate relentlessly," fosters collaboration, drives employee engagement, and ultimately enhances client service and impact. * **Leveraging Peer Networks:** Joining collaborative networks like the True Network of Advisors provides access to shared resources, best practices, marketing support, learning & development, and real-time peer-to-peer problem-solving, enabling firms to deliver advanced solutions and compete effectively. * **AI for Consultant Augmentation:** Agentic AI is poised to automate time-consuming, menial tasks such as RFP data extraction, proposal comparison, and "quote-to-card" processes. This automation will free up human consultants to focus on high-value strategic thinking, complex problem-solving, and deep client engagement. * **Benefits Drive Business Valuation:** Optimizing employee benefits can directly impact a company's financial valuation. For example, a $1.5 million saving on a $10.5 million benefits program, at a 7x valuation, translates to $10.5 million in value creation for the business. * **Reframing Self-Funding:** Instead of presenting self-funding as a risky proposition, consultants should reframe it as a strategic financing decision for an expense a company is already committed to spending, highlighting the greater control and potential for cost savings. * **Data-Driven Plan Optimization:** Effective consulting requires leveraging historical plan performance data to identify inefficiencies, weak spots, and opportunities for improvement, aligning these insights with the client's business strategy for a multi-year approach. * **Effective Change Management:** Successful implementation of new benefits programs relies on a methodical change management strategy that identifies communication pathways, addresses both objective facts and subjective concerns (fears), and includes post-mortem feedback for continuous improvement. * **Addressing Pharmacy Spend:** Significant cost savings can be achieved by scrutinizing Pharmacy Benefit Manager (PBM) rebates, exploring cash-based pharmacy models, and utilizing international sourcing for prescription drugs, which can dramatically reduce out-of-pocket costs for members. * **Enhancing Member Experience:** Innovations like virtual mental health platforms (e.g., Headway) improve access to care, while cost transparency tools (e.g., Healthcare Bluebook) and "episode of care" pricing programs provide members with greater predictability and control over their healthcare expenses. * **Fiduciary Responsibility and Transparency:** Employers have a fiduciary obligation to ensure that their benefit plans are being charged on a fair and reasonable basis, necessitating a push for greater transparency and accountability from carriers and vendors. * **Future Focus on Cost & Quality:** The industry is moving towards a better integration of cost and quality data, aiming to reward high-performing providers and make quality information visible to consumers, ultimately leading to better healthcare outcomes. **Tools/Resources Mentioned:** * **True Network of Advisors:** A peer network for benefits consultants providing resources, collaboration, and support. * **Paro Health:** Mentioned as a large benefits captive making self-insurance more accessible for small to mid-size employers. * **Patient:** A program offering a virtual visa for out-of-pocket medical, dental, vision, and pet expenses, allowing 12-month, no-recourse payback. * **Headway:** A platform acting as a back office for individual psychologists and psychiatrists, improving access to mental health services. * **Healthcare Bluebook:** A tool for identifying better-priced or higher-quality healthcare. * **CRX:** A service for international drug sourcing, mentioned for significant prescription cost savings. * **Assurist / Careway:** Programs mentioned for providing total cost of care or episode of care costs. * **Plan Site:** (Mentioned by host) A previous company that utilized AI for RFP processing and benchmarking benefits. **Key Concepts:** * **Strategic Consultant:** An evolved role in the benefits industry that moves beyond transactional brokering to align employee benefits programs with a company's overarching business strategy and C-suite objectives, focusing on value creation and long-term impact. * **Self-Funding:** A healthcare financing model where an employer assumes the financial risk for providing healthcare benefits to its employees, rather than paying fixed premiums to an insurance carrier. This offers greater control over plan design and potential cost savings. * **Agentic AI:** The application of artificial intelligence where autonomous "agents" perform specific tasks, automate processes, and act as intelligent assistants, particularly in data-intensive or repetitive administrative functions within consulting. * **Reference-Based Pricing (RBP):** A healthcare payment model where providers are reimbursed based on a reference price (often a multiple of Medicare rates) rather than relying on negotiated network rates, aiming to introduce transparency and control costs. * **Leave a Ladder Philosophy:** A cultural value that encourages individuals, upon achieving success or carving out a new path, to make it easier for others to follow and benefit from their experience, fostering mentorship and collective growth. * **Total Cost of Care / Episode of Care:** Programs or approaches that aim to provide a comprehensive, upfront cost for a specific medical condition or treatment episode, offering greater cost certainty to members and employers.
The Future of Veeva Services: Strategic Transformation Insights from Our Experts
Everest Group
/@EverestGroup
Nov 17, 2025
This Q&A session, featuring experts from Everest Group, provides an in-depth analysis of the rapidly evolving Veeva services landscape and its role in strategic transformation within the life sciences industry. The discussion is framed by the context of a recent assessment of over 30 service providers in the Veeva ecosystem. The central theme is the shift in mindset among life sciences companies, moving away from siloed, one-off IT projects toward building comprehensive, platform-driven digital ecosystems—with Veeva, alongside platforms like Salesforce and IQ, forming the digital backbone necessary for scalability, data integrity, and regulatory compliance. The experts identify three critical differentiators separating top-performing service providers in the dynamic Veeva environment. First, successful providers are productizing their Intellectual Property (IP), moving beyond simple implementation to packaging migration toolkits and accelerators that can be reused across multiple clients. Second, they are embedding deep consulting and advisory capabilities, engaging with clients early to shape roadmaps well before an RFP is issued. Third, and most crucially, these leaders are embedding responsible Artificial Intelligence (AI) into their solutions. This integration is seen as non-negotiable for future success, driving efficiency and innovation across the value chain. The conversation addresses the "buzz vs. reality" of AI in the life sciences boardroom, confirming that tangible impact is already being delivered across both the development and commercial clouds. In the Development Cloud, AI is automating the generation of validation scripts and the creation of submission documents, streamlining crucial regulatory processes. On the commercial side, AI is summarizing Healthcare Professional (HCP) notes and recommending next best actions for sales teams. A major caveat highlighted is the necessity of "trust" in AI deployment, making Veeva’s certification on AI program increasingly vital. Life sciences enterprises demand that AI be deployed within a compliant environment, ensuring adherence to strict industry regulations. Looking ahead, the next phase of leadership in life sciences platform services will be defined by "orchestration"—the ability to seamlessly connect different value chain elements and various cloud platforms. The ultimate success factor for service providers will be their capacity to embed AI at every layer of the solution stack to influence business outcomes. Furthermore, the most successful clients view transformation as a partnership, co-investing in accelerators and continuous improvement rather than simply relying on the platform itself to deliver all necessary modernization. Clients who fail often make the mistake of expecting the platform alone to drive transformation, neglecting the need for co-creation with their service partners. ### Detailed Key Takeaways * **Platform Ecosystem Mindset is Mandatory:** Life sciences companies are abandoning one-off IT projects and are instead focusing on building integrated platform ecosystems (Veeva, Salesforce, IQ) that serve as the digital backbone for the organization, prioritizing scalability, data integrity, and compliance. * **Provider Differentiation through IP Productization:** Top service providers are moving beyond basic implementation services by productizing their IP, offering reusable assets like migration toolkits and accelerators to speed up deployment and deliver repeatable value to customers. * **Advisory Capabilities Precede RFPs:** Successful providers are embedding deep consulting and advisory expertise, allowing them to engage with clients early, shape strategic roadmaps, and influence transformation direction before formal Request for Proposals (RFPs) are even issued. * **Responsible AI is a Core Differentiator:** Embedding responsible AI is now a key factor separating leading Veeva service providers, requiring them to integrate AI solutions that are not only effective but also trustworthy and compliant with regulatory standards. * **AI Delivers Tangible Value in Development Cloud:** Specific AI applications are already automating critical regulatory and operational tasks, such as the automatic generation of validation scripts and the creation of submission documents within the Development Cloud. * **AI Optimizes Commercial Operations:** In the Commercial Cloud, AI is actively summarizing notes from Healthcare Professional (HCP) interactions and providing intelligent recommendations for "next best actions," significantly enhancing sales force effectiveness and commercial strategy. * **Compliance and Trust are Paramount for AI Adoption:** The widespread adoption of AI in life sciences hinges on trust and regulatory compliance; enterprises are prioritizing providers who can deploy AI solutions within a compliant environment, often referencing Veeva’s certification on AI program. * **Client Success Requires Co-Creation:** The most successful clients view transformation as a true partnership, actively co-investing in accelerators and continuous improvement initiatives rather than merely hiring a vendor and expecting the platform alone to deliver modernization. * **Avoid the Platform-Only Pitfall:** A common mistake made by clients is expecting the platform (Veeva) to automatically bring in all necessary modernization, neglecting the need for internal investment, process re-engineering, and collaborative development with service partners. * **Future Leadership Defined by Orchestration:** The next phase of leadership in platform services will be defined by the ability to "orchestrate"—connecting disparate value chain elements and integrating different cloud platforms (e.g., connecting Veeva CRM with other enterprise systems) for holistic business outcomes. * **AI Must Be Embedded at Every Layer:** Future leaders must demonstrate the capability to embed AI not just as a feature, but across every layer of the technology stack to maximize influence on core business outcomes and operational efficiency. ### Key Concepts * **Platform Ecosystems:** The strategic shift in life sciences from using individual software tools to building integrated digital backbones (like Veeva, Salesforce, IQ) that ensure enterprise-wide scalability, data integrity, and compliance. * **Productizing IP:** The practice of service providers packaging proprietary methodologies, tools, and accelerators (e.g., migration toolkits) into reusable products to increase efficiency and speed of delivery across multiple client engagements. * **Orchestration:** The future strategic imperative for service providers, focusing on connecting and coordinating different cloud platforms and value chain elements to achieve seamless, end-to-end business processes. * **Veeva's Certification on AI Program:** A regulatory-focused program that validates the compliance and trustworthiness of AI solutions deployed within the Veeva ecosystem, crucial for life sciences enterprises operating in regulated environments.
Argus vs LSMV vs Veeva The TOP 3 Interfaces for Pharmaceutical Professionals
The Drug Safety Coach
/@TheDrugSafetyCoach
Nov 16, 2025
This video provides an in-depth comparison of three prominent safety systems utilized in the pharmacovigilance domain: Oracle Argus Safety, Lives Medical Vigilance (LSMV), and Veeva Safety. The speaker, "The Drug Safety Coach," aims to elucidate the fundamental differences between these systems, explaining why organizations choose specific platforms and how they function in real-world pharmacovigilance activities, particularly focusing on their user interfaces for case processing. The discussion progresses from a high-level overview of each system's characteristics to a detailed visual walkthrough of their respective data entry tabs and workflows. The core of the comparison revolves around several key aspects: platform type, main modules, strengths, and weaknesses. Argus Safety is presented as a mature system available both on-premises and in the cloud, renowned for its regulatory compliance due to its long history, though it's noted for its complex setup. LSMV is highlighted as a cloud-native solution emphasizing automation and a user-friendly interface, albeit with a steeper learning curve. Veeva Safety, also cloud-native, is positioned for its strong integration capabilities with clinical and regulatory affairs, though it comes with a higher cost and a highly controlled setup. The video then visually demonstrates the user interfaces for case processing in each system, showcasing the various tabs for entering patient, product, event, and other case-related information, illustrating how the layout and flow differ while the underlying data entry functionality remains similar. The speaker delves into the specifics of each system's interface, starting with Argus Safety, detailing tabs like General, Patient, Product, Event, Analysis, Activities, Additional Information, and Regulatory Reports. Visual examples of the Argus Patient and Event tabs are provided. The comparison then moves to LSMV, showcasing its interface with tabs such as General Case Information, Source, Reporter, Study, Patient, Products, Event, Narrative, and Lab Data, emphasizing its open-source tab structure that enhances user-friendliness compared to Argus. Finally, Veeva Safety's interface is explored, highlighting its "vault" concept for secure information, its inbox for new cases, and customizable tabs like Details, Case, Contact, Patient, Product, Medical, Events, Documents, and Transmissions. The video concludes by reiterating that while the core functionality of data entry is similar across these systems, their interfaces, customization options, and specific strengths (e.g., Argus for regulatory compliance, LSMV for automation, Veeva for integration and control) are crucial differentiators for pharmaceutical organizations. Key Takeaways: * **Three Core Pharmacovigilance Systems:** The video provides a comparative analysis of Oracle Argus Safety, Lives Medical Vigilance (LSMV), and Veeva Safety, which are the leading safety databases used in the pharmaceutical industry for pharmacovigilance. * **Platform Deployment Models:** Argus Safety offers flexibility with both on-premises and cloud deployment options, while LSMV and Veeva Safety are exclusively cloud-native software solutions, reflecting a modern trend towards cloud infrastructure. * **Distinct Key Modules:** Each system has specialized modules: Argus focuses on case processing, reporting, and signal detection; LSMV on case intake, medical review, and reporting; and Veeva Safety (part of Veeva Vault Quality) also covers case processing, reporting, and integration. * **Strengths and Weaknesses Differentiate Choice:** Argus's strength lies in its historical regulatory compliance, making it a "gold standard." LSMV excels in automation and user interface design. Veeva Safety's strength is its robust integration with clinical and regulatory affairs, though it is noted for being expensive and having a highly controlled setup. * **User Interface and Workflow Variations:** Despite similar core functionalities for data entry, the user interfaces (UI) and workflow navigation differ significantly across the systems. Argus uses distinct tabs like Patient, Product, Event; LSMV offers a more open-source tab structure for ease of use; and Veeva Safety provides a highly customizable, vault-like environment. * **Automation and AI in Pharmacovigilance:** The video explicitly mentions that LSMV can be highly automated, bringing "automation and artificial intelligence" into case processing, which is a critical area for efficiency and accuracy in pharmacovigilance. * **Veeva's Integration and Customization:** Veeva Safety is highlighted for its ability to integrate with other Veeva products and its high degree of customization, allowing organizations to tailor workflows and data fields according to specific regulatory and operational needs. * **Regulatory Compliance as a Primary Driver:** The historical regulatory compliance of Argus is presented as a major reason for its continued dominance, especially among Contract Research Organizations (CROs), underscoring the paramount importance of compliance in pharmacovigilance. * **Learning Curve Considerations:** LSMV, despite its user-friendly interface, has a steeper learning curve, while Argus's setup is complex. These factors influence user adoption and training requirements for pharmaceutical professionals. * **Veeva as a Secure "Vault":** Veeva Safety is described as functioning like a "vault," implying a highly secure and controlled environment for managing sensitive pharmacovigilance data, which aligns with stringent industry regulations. * **Workflow Customization in Veeva:** Veeva Safety allows for extensive customization of workflows (e.g., Triage, Data Entry, Quality Review, Medical Review, Submission), enabling companies to align the system with their specific standard operating procedures. Tools/Resources Mentioned: * Oracle Argus Safety * Lives Medical Vigilance (LSMV) * Veeva Safety (part of the broader Veeva Vault ecosystem, specifically Vault Quality) Key Concepts: * **Pharmacovigilance (PV):** The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. * **Safety Systems/Databases:** Software platforms used to manage, process, and report adverse event data in pharmacovigilance. * **Case Processing:** The end-to-end process of handling an individual adverse event report, from intake to submission. * **Regulatory Compliance:** Adherence to laws, regulations, guidelines, and specifications relevant to the pharmaceutical industry (e.g., FDA, EMA, GxP, 21 CFR Part 11). * **Signal Detection:** The process of identifying new or changing safety issues related to medicinal products. * **Cloud-Native Software:** Applications designed to run in cloud environments, leveraging cloud services for scalability, resilience, and flexibility. * **On-Premises Software:** Software installed and run on computers located physically within a company's own facilities. * **User Interface (UI):** The visual elements and interactive properties of a software application that users interact with. * **Automation:** The use of technology to perform tasks with minimal human intervention, often aimed at increasing efficiency and reducing errors. * **Artificial Intelligence (AI):** The simulation of human intelligence processes by machines, especially computer systems, applied here to enhance pharmacovigilance activities like case processing.
Patients Refuse to Take Medication. Why? Approaches to Use.
AHealthcareZ - Healthcare Finance Explained
@ahealthcarez
Nov 16, 2025
This video provides an in-depth exploration of patient refusal to take medication, a critical aspect of broader medication non-adherence. Dr. Eric Bricker, from AHealthcareZ, begins by contextualizing patient refusal as a significant subcategory of non-adherence, noting that approximately 50% of patients are non-adherent to their prescribed medications. He highlights the substantial financial burden associated with non-adherence, citing a Medicare study where non-adherent patients incurred an average of $14,180 in annual medical costs, compared to $10,400 for adherent patients – a 27% increase. The core premise is that human behavior is complex and "messy," and third-party payers (employers, government) ultimately bear the financial responsibility for this variability in patient compliance. The presentation delves into the multifaceted reasons behind outright patient refusal. These include a desire for autonomy and independence from pills, deep-seated mistrust of medical institutions (exemplified by the historical Tuskegee Syphilis Study, where African-American men were intentionally left untreated for decades), pharmacophobia (fear of medications), adherence to specific cultural or spiritual beliefs favoring natural remedies, and underlying psychiatric diagnoses such as depression, bipolar disorder, or schizophrenia that can lead to loss of hope or poor insight. Additionally, past negative experiences with medication can contribute to refusal. The speaker emphasizes that clinicians must understand these diverse motivations to effectively address non-adherence, especially for life-threatening conditions like Type 1 diabetes. To counter patient refusal, Dr. Bricker introduces Motivational Interviewing, a well-studied and highly successful approach adopted by institutions like the British National Health Service. This method focuses on forming a relationship with the patient rather than employing an authoritarian or manipulative stance. Key techniques include initiating conversations by asking patients about their concerns and past experiences, actively listening without immediate persuasion, acknowledging and validating their feelings, avoiding a dictatorial tone, offering choices (e.g., starting with a lower dose or trying lifestyle changes first), normalizing their emotional responses, and facilitating peer-to-peer discussions with other patients who have successfully managed their conditions. For patients with psychiatric diagnoses, integrating counseling, such as Cognitive Behavioral Therapy (CBT), alongside medical therapy is also recommended. The video concludes by underscoring that these effective, patient-centered approaches require significant "time" – a resource often scarce in the prevalent fee-for-service primary care model. Dr. Bricker argues that an 8-15 minute visit is insufficient for motivational interviewing and advocates for alternative payment structures like subscription-based or capitated primary care, which allow for longer, more frequent patient interactions. He posits that investing in this "intervention" of time can lead to substantial healthcare cost reductions, framing it as a crucial consideration for those underwriting human behavior within the healthcare system. Key Takeaways: * **Prevalence and Cost of Non-Adherence:** Approximately 50% of patients are non-adherent to their medication, leading to significantly higher healthcare costs. Non-adherent patients in a Medicare study incurred $3,800 more annually (27% higher) in medical expenses compared to adherent patients. * **Diverse Reasons for Refusal:** Patient refusal is complex, stemming from a desire for autonomy, mistrust of medical institutions (e.g., the Tuskegee Syphilis Study), pharmacophobia, cultural/spiritual beliefs, psychiatric diagnoses (depression, schizophrenia), and prior negative medication experiences. * **Clinician's Responsibility:** Healthcare providers have a critical role in understanding and addressing patient refusal, particularly for conditions where non-adherence can lead to severe health consequences or death (e.g., Type 1 diabetes). * **Motivational Interviewing (MI) as a Solution:** MI is an evidence-based, patient-centered communication approach proven highly effective in addressing medication non-adherence and fostering behavior change, successfully adopted in various healthcare systems. * **Core Principles of MI:** Effective MI involves asking open-ended questions about patient concerns, active and non-judgmental listening, acknowledging and validating patient feelings, avoiding an authoritarian approach, and offering choices to empower the patient in their treatment plan. * **Empowering Choices:** Clinicians should offer patients choices, such as starting with a lower dose, taking fewer pills, or exploring lifestyle changes before medication, to increase their sense of control and adherence. * **Normalizing Emotional Responses:** It is crucial to normalize patients' emotional responses and feelings about medication, rather than dismissing them, to build trust and facilitate open communication. * **Leveraging Peer Support:** Encouraging patients to speak with peers who have successfully managed similar conditions can be a powerful tool for building confidence and trust, as information from a fellow patient can often be more impactful than from a clinician. * **Integrated Mental Health Support:** For patients with psychiatric diagnoses, combining medical therapy with counseling, such as Cognitive Behavioral Therapy (CBT), is essential for improving medication adherence and overall treatment outcomes. * **The "Time" Factor in Care:** Effective patient engagement strategies like Motivational Interviewing are time-intensive, requiring longer and more frequent patient visits than typically allowed in traditional fee-for-service primary care models. * **Systemic Barriers to Adherence:** The fee-for-service primary care model, with its short visit times, is identified as a significant barrier to implementing comprehensive adherence interventions, highlighting a need for systemic change. * **Investment in Time Yields Returns:** Investing in healthcare models that prioritize clinician-patient time (e.g., subscription-based or capitated primary care) can lead to substantial reductions in overall healthcare costs by improving patient adherence and health outcomes. Key Concepts: * **Non-adherence:** The failure of patients to take their medication as prescribed, including not filling prescriptions, forgetting doses, or discontinuing due to side effects. * **Patient Refusal:** A specific form of non-adherence where a patient explicitly declines to take prescribed medication. * **Pharmacophobia:** An irrational fear of taking medications. * **Motivational Interviewing (MI):** A collaborative, goal-oriented style of communication with particular attention to the language of change. It is designed to strengthen personal motivation for and commitment to a specific goal by eliciting and exploring the person's own reasons for change within an atmosphere of acceptance and compassion. * **Cognitive Behavioral Therapy (CBT):** A type of psychotherapy that helps patients identify and change destructive thought patterns and behaviors that have a negative influence on emotions and behaviors. * **Fee-for-service primary care:** A healthcare payment model where providers are reimbursed for each service they provide, often incentivizing volume over time spent with patients. * **Subscription-based/Capitation primary care:** Alternative payment models where providers receive a fixed payment per patient over a period, encouraging comprehensive care and longer patient interactions. Examples/Case Studies: * **Tuskegee Syphilis Study:** A historical example of medical institutional mistrust, where the U.S. Public Health Service withheld treatment from African-American men with syphilis from the 1930s to the 1970s to study the natural progression of the disease. * **Type 1 Diabetes:** Used as a critical example where insulin adherence is vital to prevent severe complications like diabetic ketoacidosis and death, underscoring the high stakes of patient refusal. * **Medicare Population Study:** Data cited indicating that non-adherent patients had average medical costs of $14,180 per year, while adherent patients had costs of $10,400 per year, demonstrating a 27% cost reduction with adherence.
Optimizing Spark Performance Through Intelligent Data Preprocessing | Gadi Goren , Veeva |
DataFlint
/@Dataflint
Nov 13, 2025
This video provides an in-depth exploration of optimizing Apache Spark performance through intelligent data preprocessing, presented by Gadi Goren from Veeva. The core purpose of the talk is to share practical solutions for common data engineering challenges encountered in production environments, specifically within the context of processing large volumes of commercial and health-related data for pharmaceutical clients. Goren begins by establishing the business context, explaining that their clients are pharmaceutical companies keen on understanding the effectiveness of their advertising campaigns by combining commercial ad impression data with anonymous health data. The presentation details how an external data preprocessing layer, dubbed "Pioneer," significantly enhances the efficiency and reliability of subsequent Spark-based data processing. The speaker delves into three primary problems that often plague Spark pipelines: the "small file problem" (many small input files), the "large file problem" (single or few very large input files), and the challenge of "schema evolution" (inconsistent schemas across input files). He explains how these issues lead to Spark driver overload, S3 slowdowns, inefficient task management, "struggler tasks" causing idle clusters, and job failures due to schema mismatches. The proposed solution involves introducing a dedicated preprocessing stage *before* data enters Spark, ensuring that Spark receives uniformly prepared, "Spark-ready" data. This stage handles tasks like splitting oversized files, consolidating numerous small files into optimally sized ones (e.g., 100MB), and converting data to efficient formats like Parquet, while also managing schema alignment. Goren elaborates on their implementation using AWS Step Functions with the Distributed Map feature, leveraging lightweight, I/O-bound containers to process data in parallel. This approach is highlighted as being fast, cost-effective, and highly scalable. The benefits demonstrated include significantly improved Spark efficiency and predictability, eliminating production slowdowns and crashes caused by unpredictable input data. Through a demo, the speaker illustrates the substantial speedup achieved by offloading these preprocessing tasks from Spark, allowing Spark to focus on its core strengths of data transformation and analysis rather than infrastructure management. The discussion also touches upon the evolution of their solution, moving from an all-Spark approach to this hybrid model after encountering severe performance and stability issues, particularly with schema merging. Key Takeaways: * **Business Context for Data Processing:** The speaker's company processes vast amounts of commercial advertising data combined with anonymous health data for pharmaceutical clients to assess campaign effectiveness, highlighting a critical use case for robust data pipelines in the life sciences sector. * **Challenges of Unpredictable Data Input:** Data arriving from external partners (DSPs, SSPs, publishers) is often inconsistent in terms of file size (many small files or very large files), format, and schema, leading to significant performance bottlenecks and failures in Spark. * **The "Small File Problem" in Spark:** Numerous small files cause Spark driver overload, excessive S3 API calls leading to slowdowns, and inefficient cluster utilization as Spark spends more time managing metadata and partitions than processing data. * **The "Large File Problem" in Spark:** Single, large, compressed files (e.g., GZIP) can lead to "struggler tasks" where one executor works intensely while others remain idle, causing severe slowdowns or out-of-memory errors and cluster crashes. * **Schema Evolution and Inconsistency:** Varying schemas across input files can cause Spark to infer incorrect schemas, leading to data corruption or job failures when encountering unexpected data types. Spark's internal schema merge process is often expensive and inefficient. * **Solution: External Data Preprocessing Layer:** Implement a dedicated preprocessing stage *before* data enters Spark. This stage prepares "Spark-ready data" by standardizing file sizes, formats, and schemas, allowing Spark to operate more efficiently and predictably. * **Preprocessing Operations:** Key preprocessing tasks include splitting large files into smaller, manageable chunks; consolidating many small files into optimally sized files (e.g., 100MB); converting data to efficient columnar formats like Parquet; and harmonizing schemas. * **AWS-Based Implementation:** The specific solution leverages AWS Step Functions with its Distributed Map feature, running parallel processes on lightweight, I/O-bound containers. This approach is described as fast, cost-effective, and scalable for handling massive data volumes. * **Significant Performance Gains:** Demonstrations show substantial speedups (e.g., 5x for small file problem, 3x for schema merge) when preprocessing is done externally, validating the investment in this additional stage. * **Predictable Spark Performance:** The preprocessing layer ensures consistent input for Spark, leading to predictable job runtimes and stability, regardless of whether processing daily incremental data or large historical backfills, thereby preventing unexpected production issues. * **Cost-Effectiveness of Preprocessing:** Despite being an additional step, the preprocessing stage is very low-cost and quick (minutes to tens of minutes for data volumes that would take hours in Spark), making it a worthwhile investment for overall pipeline efficiency. * **Handling S3 Limits:** The external preprocessing allows for controlled parallelism, preventing S3 slowdowns by staying within read limits (e.g., ~500 files/second), unlike dynamic Spark clusters that might exceed these limits. * **Evolutionary Solution Development:** The current preprocessing approach was developed iteratively after encountering severe limitations and failures when attempting to handle all data quality and formatting issues directly within Spark. * **Data Lake Technology:** The company utilizes Apache Hudi as its data lake format, indicating a focus on transactional data lakes and efficient data management. Tools/Resources Mentioned: * **Apache Spark:** The primary big data processing framework being optimized. * **AWS Step Functions:** An AWS service used to coordinate distributed applications and microservices, specifically for orchestrating the preprocessing workflow. * **AWS Step Functions Distributed Map:** A feature within Step Functions that allows for running many parallel iterations of a step, ideal for processing large datasets. * **AWS S3:** Amazon Simple Storage Service, used for storing raw input data from partners and processed data. * **Parquet:** A columnar storage file format optimized for analytics, used for storing "Spark-ready" data. * **Apache Hudi:** A data lake platform that enables transactional data lakes, mentioned as the format for their data lake. Key Concepts: * **Data Preprocessing:** The process of transforming raw data into a clean and organized format suitable for analysis or further processing. In this context, it specifically refers to preparing data for optimal ingestion by Apache Spark. * **Small File Problem:** A common issue in big data systems where processing many small files leads to high overhead for metadata management, inefficient resource utilization, and performance degradation. * **Large File Problem:** The challenge of processing extremely large files, especially compressed ones, which can lead to single-node bottlenecks ("struggler tasks") and resource contention in distributed systems. * **Schema Evolution:** The process of adapting to changes in the structure (schema) of data over time. Inconsistent schema evolution can break data pipelines if not handled gracefully. * **Spark Driver Overload:** A state where the Spark driver, responsible for coordinating tasks, becomes overwhelmed by the volume of metadata or tasks, leading to slowdowns or crashes. * **Struggler Tasks:** Tasks in a distributed computing environment that take significantly longer to complete than others, often due to data skew or resource contention, slowing down the entire job. * **I/O Bound:** A process or system whose performance is limited by the speed of input/output operations (e.g., reading from or writing to disk/network) rather than CPU processing. * **Spark-Ready Data:** Data that has been preprocessed and formatted in a way that is highly optimized for ingestion and processing by Apache Spark, ensuring efficiency and stability.
Metazoa Automates the Transition from Veeva CRM to Life Sciences Cloud
Metazoa
/@metazoa6598
Nov 13, 2025
This video provides an in-depth exploration of automating the complex transition from Veeva CRM to Salesforce Life Sciences Cloud (LSC) using Metazoa Snapshot. The presenter begins by highlighting the significant challenges inherent in such a migration, which involves thousands of metadata assets, deeply interconnected automations, managed package dependencies, and mission-critical datasets requiring precise mapping, movement, and validation. The core purpose of the video is to demonstrate how Metazoa Snapshot streamlines this intricate process, transforming what typically takes months into a fast, controlled, and repeatable operation. The methodology presented is a six-step workflow designed to ensure precision and efficiency. It starts with preparing both the existing Veeva CRM org (source) and a brand-new Life Sciences Cloud org (target) by connecting them to Snapshot. The tool then automatically analyzes the entire metadata landscape—including objects, fields, flows, validation rules, triggers, and layouts—to create a comprehensive inventory. A unique innovation, "Shell Assets," is then introduced, which generates a lightweight "skeleton" of every asset from the source environment. These shell assets, containing object definitions, field structures, automation placeholders, and page layout scaffolding, deploy extremely fast into the target LSC org, even across products with different feature sets, allowing the LSC org to mirror the original structure without being blocked by Veeva-specific dependencies. Following the rapid deployment of Shell Assets, which may involve safely removing 30-40 standard metadata conflicts due to differences between the orgs, the LSC environment becomes a clean, accurate, and high-performance clone. Before migrating actual data, the video emphasizes the critical step of disabling automations such as flows, validation rules, and Apex triggers using Snapshot's "Automation Switchboard." This bulk deactivation prevents accidental processing during the data import phase. Subsequently, Snapshot's robust Data Migration engine is employed to map Veeva's managed objects to Life Sciences Cloud standard objects and migrate multi-million-record datasets, including parent-child relationships, files, and attachments, with automatic reference resolution. The final step involves replacing the temporary Shell Assets with the full, real metadata implementation, which is expedited because the underlying structure is already in place. This comprehensive workflow underscores Metazoa Snapshot's utility as a leading platform for various Salesforce transformations. It's not just about cloud migrations but also addresses org transformations, technical debt elimination, schema modernization, and metadata intelligence. The video implicitly showcases a strategic approach to managing the evolution of Salesforce environments, particularly for regulated industries like life sciences, where precision, control, and compliance are paramount. The ability to track all changes using built-in Time Series tracking further enhances control and auditability throughout the migration process. Key Takeaways: * **Complexity of Veeva CRM to LSC Migration:** Migrating from Veeva CRM to Salesforce Life Sciences Cloud is identified as one of the most complicated transformations due to thousands of metadata assets, deeply interconnected automations, managed package dependencies, and mission-critical data. * **Metazoa Snapshot's Automation:** The Metazoa Snapshot tool automates the entire transition process, converting a months-long effort into a fast, controlled, and repeatable operation, thereby enhancing efficiency and reducing manual errors. * **Innovative Shell Assets:** Shell Assets are a key innovation, creating a lightweight "skeleton" of metadata assets (object definitions, field structures, automation placeholders) that deploy rapidly. This allows the target LSC org to mirror the source org's shape without being hindered by Veeva-specific dependencies. * **Phased Deployment Strategy:** The migration follows a strategic phased approach: first, deploy shell assets to establish structure; second, migrate data; and third, replace shell assets with full, real metadata. This ensures a clean, fast, and dependency-free final deployment. * **Comprehensive Metadata Analysis:** Snapshot automatically analyzes the entire metadata landscape of both source (Veeva CRM) and target (LSC) orgs, providing a deep inventory of all deployable assets, which is crucial for planning and executing the migration. * **Automation Switchboard for Data Integrity:** The "Automation Switchboard" is a critical feature that allows for bulk deactivation of automations (flows, validation rules, Apex triggers) before data migration. This prevents accidental processing and ensures data integrity during the import phase. * **Enterprise-Grade Data Migration:** Snapshot's data migration engine is built for complex enterprise datasets, capable of handling multi-million-record migrations, parent-child relationships, files, attachments, and automatically mapping Veeva's managed objects to LSC standard objects. * **Handling Metadata Conflicts:** The tool effectively flags and allows for the safe removal of metadata conflicts (e.g., standard objects not available in LSC), streamlining the deployment process and ensuring a clean target environment. * **Time Series Tracking:** Built-in Time Series tracking records all changes made during the migration, providing an audit trail and enhancing control over the transformation process, which is particularly valuable in regulated industries. * **Broader Applicability:** While demonstrated for Veeva to LSC migration, the workflow and Metazoa Snapshot's capabilities extend to other critical Salesforce initiatives such as general org transformations, cloud migrations, technical debt elimination, schema modernization, and AI-powered admin workflows. * **Precision and Control:** The entire process emphasizes unmatched precision and control, which is vital for mission-critical transitions and ensuring regulatory compliance in the pharmaceutical and life sciences sectors. Tools/Resources Mentioned: * **Metazoa Snapshot:** The primary platform demonstrated for automating Salesforce org transformations and cloud migrations. * **Automation Switchboard:** A feature within Snapshot for bulk deactivating automations (flows, validation rules, workflow rules, Apex triggers, duplicate rules, assignment/auto-response rules). * **Time Series Tracking:** A built-in feature for recording and monitoring all metadata changes within an org. Key Concepts: * **Veeva CRM:** A leading CRM platform specifically designed for the pharmaceutical and life sciences industries. * **Salesforce Life Sciences Cloud (LSC):** Salesforce's industry-specific cloud solution tailored for life sciences companies. * **Shell Assets:** A unique Metazoa innovation that creates a lightweight, deployable "skeleton" of metadata assets to quickly establish the structural shape of a target org. * **Metadata:** Data that describes other data; in Salesforce, this includes objects, fields, layouts, flows, validation rules, triggers, etc. * **Data Migration:** The process of transferring data from one system or format to another, often involving mapping and transformation. * **Org Transformation:** The process of significantly changing or modernizing a Salesforce organization, including migrations, consolidations, or schema updates. * **Cloud Migration:** The process of moving data, applications, or other business elements to a cloud computing environment, in this context, moving from one Salesforce-based cloud (Veeva CRM) to another (LSC).
Argus vs LSMV vs Veeva — What’s the Difference ”
The Drug Safety Coach
/@TheDrugSafetyCoach
Nov 13, 2025
This video provides a concise yet critical comparison of the three leading software platforms dominating the pharmaceutical pharmacovigilance (PV) landscape: Argus Safety, LifeSphere Medical Vigilance (LSMV), and Veeva Safety. The core purpose of the analysis is to delineate the fundamental differences in design philosophy among these systems, despite their shared ultimate goal of ensuring patient safety and regulatory compliance. The comparison serves as an essential overview for professionals involved in drug safety, regulatory affairs, clinical operations, and the technology infrastructure supporting these functions. The analysis structures the comparison around three distinct archetypes of PV systems. Argus Safety is positioned as the industry classic, characterized as a powerful, rule-driven system utilized by nearly every major pharmaceutical company. This description implies a robust, mature platform built on complex, established business logic, often associated with on-premise or highly customized deployments that require significant maintenance and specialized expertise. Conversely, LifeSphere Medical Vigilance (LSMV) is highlighted as the "automation king," emphasizing a modern approach with a faster user interface and, crucially, AI-assisted workflows. LSMV represents the shift toward leveraging advanced technology, such as machine learning and potentially Large Language Models (LLMs), to streamline case processing, signal detection, and data entry, making it ideal for organizations prioritizing efficiency and modern cross-functional operations. Finally, Veeva Safety is presented as the clean, cloud-native solution, distinguished by its full integration capabilities with other regulatory and clinical systems. This integration is a key differentiator, suggesting that Veeva aims to break down data silos between safety, clinical trials, and regulatory submission processes. Being cloud-native aligns with modern enterprise IT strategies, offering scalability, easier updates, and a potentially lower total cost of ownership compared to legacy systems. While all three platforms serve the same critical function—managing adverse event reporting and ensuring drug safety—their architectural and operational differences necessitate strategic consideration when pharmaceutical companies select or upgrade their PV technology stack. Key Takeaways: • **Strategic PV System Selection:** The choice among Argus, LSMV, and Veeva Safety is not merely functional but strategic, reflecting an organization’s priorities regarding legacy integration, automation appetite, and cloud adoption strategy. • **Argus Safety as the Legacy Standard:** Argus is defined by its rule-driven architecture and widespread adoption among large pharmaceutical firms, signifying its proven reliability and deep customization capabilities, often requiring specialized data engineering to interface with modern BI tools. • **LSMV’s Focus on AI-Driven Efficiency:** LifeSphere Medical Vigilance (LSMV) differentiates itself through automation and AI-assisted workflows, presenting a strong case for companies seeking to drastically reduce manual effort in case processing and leverage intelligent tools for faster, more accurate data handling. • **Veeva Safety’s Integration Advantage:** Veeva Safety’s primary value proposition is its cloud-native architecture and seamless integration with broader regulatory and clinical systems, facilitating a unified data environment essential for streamlined compliance and end-to-end data traceability. • **Implications for Data Engineering:** The differences in system architecture (rule-driven vs. cloud-native) directly impact data engineering requirements, necessitating varied approaches for building robust data pipelines, ensuring GxP compliance, and integrating safety data into enterprise business intelligence dashboards. • **Opportunity for AI Enhancement:** LSMV’s native AI capabilities set a benchmark, but there is a significant opportunity for AI consulting firms to develop custom LLM agents or automation layers to enhance case intake, medical coding, and regulatory reporting within Argus and Veeva environments. • **Cloud Migration and Scalability:** Veeva Safety’s cloud-native design appeals to companies undergoing digital transformation, offering superior scalability and reducing the operational burden associated with maintaining complex, on-premise PV infrastructure common with older Argus deployments. • **Regulatory Compliance and Audit Trails:** The design philosophy of each system impacts how audit trails are generated and maintained; rule-driven systems like Argus offer established compliance pathways, while cloud-native systems like Veeva must demonstrate robust 21 CFR Part 11 adherence in a modern, integrated environment. • **User Experience and Workflow Modernization:** LSMV’s emphasis on a faster UI and modern workflows addresses the need for improved productivity among drug safety specialists, a critical factor often overlooked in legacy PV systems. Tools/Resources Mentioned: * Argus Safety * LifeSphere Medical Vigilance (LSMV) * Veeva Safety Key Concepts: * **Pharmacovigilance (PV):** The process of monitoring and assessing the safety of medicines after they are licensed for use, including adverse event reporting. * **Rule-Driven Systems:** Software platforms where business logic and workflows are governed by predefined, often complex, regulatory and operational rules, typical of established enterprise software. * **AI-Assisted Workflows:** The integration of artificial intelligence and machine learning tools to automate or enhance specific steps within a business process, such as case triage or data extraction in PV. * **Cloud-Native:** Software designed specifically to run in a cloud environment, leveraging services like scalability, microservices, and continuous delivery, facilitating integration across the enterprise.